Ampicillin

Authoritative Clinical Reference

DRUG NAME: Ampicillin

INN: Ampicillin
USAN: Ampicillin (same as INN — no difference)

ℹ️ Ampicillin is available as two salt forms for different routes of administration:

Ampicillin trihydrate — used in oral formulations (capsules, dry syrups)
Ampicillin sodium — used in parenteral formulations (IV, IM injections)

All doses in this monograph are expressed as ampicillin base equivalent unless otherwise specified. The salt forms are not clinically interchangeable by route (one is oral, the other parenteral), but dosing is standardised to the base.

Therapeutic Class:

Antibiotic (Antibacterial)

Subclass:

Aminopenicillin (broad-spectrum penicillin without beta-lactamase inhibitor)

Schedule (India):

Schedule H

All formulations (oral and injectable) of ampicillin fall under Schedule H of the Drugs and Cosmetics Act. Dispensing requires a valid prescription from a registered medical practitioner. No formulation has OTC status in India.

Route(s):

Oral (capsules, powder for oral suspension)
IV bolus (slow IV injection over 3–5 minutes)
IV infusion (intermittent infusion over 15–30 minutes)
IM (deep intramuscular injection)

ℹ️ The IV and IM routes are preferred for moderate-to-severe infections, meningitis, and sepsis. Oral route is appropriate for mild-to-moderate infections and step-down therapy.

Biosimilar Status:

Not a biologic — biosimilar classification not applicable. Ampicillin is a small-molecule chemical drug. Multiple generic manufacturers produce ampicillin in India.

Formulations Available in India:

Single-ingredient formulations:

Dosage Form	Strengths Available	Salt Form
Capsules	250 mg, 500 mg	Ampicillin trihydrate
Powder for oral suspension (dry syrup)	125 mg/5 mL, 250 mg/5 mL (reconstituted volume typically 60 mL or 100 mL)	Ampicillin trihydrate
Powder for injection (vial)	250 mg, 500 mg, 1 g	Ampicillin sodium

Clinically relevant Fixed-Dose Combinations (FDCs) available in India:

FDC	Formulation	Strengths Available	Clinical Rationale
Ampicillin + Sulbactam	Powder for injection	1 g + 0.5 g (1.5 g vial), 2 g + 1 g (3 g vial)	Sulbactam is a beta-lactamase inhibitor — extends coverage to beta-lactamase-producing organisms
Ampicillin + Cloxacillin	Capsules	250 mg + 250 mg, 500 mg + 500 mg	Combined gram-negative (ampicillin) + anti-staphylococcal (cloxacillin) coverage
Ampicillin + Cloxacillin	Powder for injection	250 mg + 250 mg, 500 mg + 500 mg	As above, parenteral form
Sultamicillin	Tablets	375 mg (mutual prodrug of ampicillin + sulbactam; delivers ~220 mg ampicillin + ~147 mg sulbactam)	Oral prodrug form of ampicillin-sulbactam combination

ℹ️ No ampicillin-containing FDC is currently listed as banned by CDSCO. Prescribers should verify against the latest CDSCO banned FDC list, as this is updated periodically.

💡 Device note: No special device required. Oral suspension requires reconstitution with water before dispensing (see Reconstitution section). Injectable formulations require standard sterile reconstitution.

PHARMACOKINETICS

Primary PK Table — Oral and Parenteral Routes:

Parameter	Value
Bioavailability (oral)	~40–50%. Significantly reduced by food (by up to 50%). Take on an empty stomach for optimal absorption.
Tmax	Oral: 1–2 hours; IM: ~1 hour; IV bolus: end of injection (immediate peak)
Protein binding	~15–28% (low; predominantly to albumin)
Volume of distribution (Vd)	0.2–0.3 L/kg. Distributes well into body fluids including peritoneal fluid, pleural fluid, middle ear effusions, bile, and bronchial secretions. Achieves therapeutic CSF concentrations only when meninges are inflamed (10–30% of serum levels with inflamed meninges vs <1% with intact meninges). Crosses the placenta. Enters breast milk in low concentrations.
Metabolism	Minimal hepatic metabolism (~10–15%). Partially hydrolysed to penicilloic acid (microbiologically inactive). Not a substrate, inhibitor, or inducer of any clinically relevant CYP enzyme. Drug transporter profile: Substrate of OAT1 and OAT3 (organic anion transporters in the renal tubule — mediates active tubular secretion). Not a clinically significant P-glycoprotein substrate. Not a significant substrate of OATP1B1/1B3, BCRP, OCT2, or MATE1/2.
Half-life (t½)	Adults with normal renal function: 1–1.8 hours. Prolonged in renal impairment: mild (2–4 hours), severe/ESRD (7–20 hours). Prolonged in neonates: term neonates 2–4 hours, preterm neonates 4–6 hours.
Excretion	Primarily renal: ~60–80% excreted unchanged in urine via both glomerular filtration and active tubular secretion. ~10% excreted via biliary route. Small amount recovered in faeces.
Dialysability	Yes — significantly removed by haemodialysis (20–50% removed in a standard 4-hour session). Supplemental dose required post-dialysis. Moderately removed by peritoneal dialysis. Removed by CRRT — dose adjustment needed (see Renal Adjustment).
Food effect	⚠️ Food significantly reduces and delays absorption. Oral ampicillin should be taken on an empty stomach: 1 hour before meals or 2 hours after meals.
Onset of action	IV: Rapid — therapeutic serum levels achieved within minutes of injection. IM: 30–60 minutes. Oral: 1–2 hours. Clinical response in infections typically begins within 48–72 hours.
Duration of action	~4–6 hours (time-dependent killing — efficacy depends on time above MIC, not peak concentration). Requires dosing every 6 hours (q6h) for most indications; every 4 hours (q4h) for severe/meningeal infections.

Prodrug status: Ampicillin itself is NOT a prodrug. However, sultamicillin (the oral FDC prodrug) is a double ester of ampicillin and sulbactam — it is hydrolysed by intestinal esterases during absorption to release ampicillin and sulbactam. Bacampicillin and pivampicillin are oral prodrugs of ampicillin with higher bioavailability (~80–90%) but are not commonly available in current Indian market.

Non-linear PK: No clinically significant non-linear pharmacokinetics at therapeutic doses. Renal excretion follows first-order kinetics.

Pharmacodynamic note — Time-dependent killing:
💡 Ampicillin (like all beta-lactams) exhibits time-dependent bactericidal activity. The key PK/PD parameter for efficacy is fT > MIC (fraction of the dosing interval during which the free drug concentration exceeds the minimum inhibitory concentration of the pathogen). The target is typically fT > MIC ≥ 40–50% for bactericidal effect and ≥ 60–70% for maximal killing. This has direct implications for dosing:

Shorter dosing intervals (q6h or q4h) are more effective than fewer large doses
Continuous or prolonged IV infusion may be beneficial in critically ill patients (evidence emerging but not yet standard practice in India)

Population PK Notes:

Population	Clinically Significant PK Difference
Obesity	Vd (L/kg) may be modestly increased based on total body weight. For serious infections, use actual body weight for dose calculation rather than ideal body weight. Limited formal PK data in obese patients.
Pregnancy	⚠️ GFR increases by 40–65% during pregnancy → increased renal clearance → lower serum levels of ampicillin. For serious infections (e.g., GBS intrapartum prophylaxis), higher loading doses and short dosing intervals are used (see Indications). Vd also increases modestly due to expanded plasma volume.
Critical illness / ICU	⚠️ Vd significantly increased in sepsis, burns, and fluid-overloaded states → lower serum concentrations. Augmented renal clearance (ARC; CrCl >130 mL/min) common in young, non-elderly ICU patients with sepsis or trauma → subtherapeutic levels with standard dosing. Consider higher doses, more frequent dosing (q4h), or prolonged/continuous IV infusion in the ICU setting. Hypoalbuminaemia has minimal impact (low protein binding).
Paediatric	Neonates (especially preterm) have significantly prolonged half-life due to immature renal function and larger Vd per kg. Term neonates: t½ ~2–4 hours; preterm neonates: t½ ~4–6 hours. Dosing interval is extended to q8h or q12h in neonates (age/weight dependent). Children >1 month: weight-adjusted clearance and Vd similar to adults; standard q6h dosing interval applies.
Elderly (≥60 years)	Half-life moderately prolonged due to age-related decline in renal function. Dose adjustment based on eGFR rather than age alone. No inherent change in Vd or protein binding beyond what renal function adjustment covers.

ADULT INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

⚠️ Critical Prescribing Context for Ampicillin in India:

Before detailing individual indications, prescribers must note the following overarching points that apply across ALL indications:

Resistance landscape in India: Ampicillin resistance rates among common Gram-negative pathogens (E. coli, Klebsiella spp., non-typhoidal Salmonella) in India are very high (>70–90% in many institutional antibiograms). Empirical use of ampicillin alone for suspected Gram-negative infections (UTIs, intra-abdominal, enteric fever) is generally not recommended without prior susceptibility data or strong clinical/epidemiological grounds.
Ampicillin retains reliable activity against:Listeria monocytogenes (no known resistance), Enterococcus faecalis (most strains — check local antibiogram for VRE rates), Group B Streptococcus (GBS) (nearly universal susceptibility), Streptococcus pneumoniae (most non-meningeal isolates in India), Streptococcus pyogenes (universal susceptibility), Proteus mirabilis (variable — check susceptibility).
Oral route limitation: Oral ampicillin has lower bioavailability (~40–50%) than oral amoxicillin (~70–90%). For most indications where an oral aminopenicillin is appropriate, amoxicillin is preferred over oral ampicillin. Oral ampicillin remains relevant as step-down therapy and where amoxicillin is unavailable.
Time-dependent killing: All doses should be administered at regular, evenly spaced intervals (q6h or q4h). Missed or irregularly timed doses significantly reduce efficacy. Counsel patients/staff accordingly.

Primary Indications (Approved / Standard in India)

1. Bacterial Meningitis — Listeria monocytogenes

Context: Ampicillin is the drug of choice for Listeria monocytogenes meningitis and should be included as empirical coverage in patients at risk for Listeria (age >50 years, neonates, immunocompromised, pregnant women, alcoholics, patients on corticosteroids) presenting with meningitis.

Route Table:

Route	Starting / Standard Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
IV bolus (slow push over 3–5 min)	2 g IV stat	Not applicable	2 g IV every 4 hours	Max 2 g per dose; Max 12 g per day	Preferred route for meningitis. Must achieve adequate CSF penetration.
IV infusion (intermittent, over 15–30 min)	2 g IV stat	Not applicable	2 g IV every 4 hours	Max 2 g per dose; Max 12 g per day	May be preferred to reduce injection-site phlebitis

Duration: Minimum 21 days for confirmed Listeria meningitis. May be extended to 28 days in immunocompromised patients.

Combination therapy: Often combined with gentamicin (for synergistic bactericidal activity against Listeria) for at least the first 7–14 days. Gentamicin dose: 5 mg/kg/day IV in 2–3 divided doses (adjust for renal function).

Mandatory Clinical Notes Checklist:

When to prefer this drug over alternatives: Ampicillin is the first-line and only reliably effective drug for Listeria meningitis. No beta-lactam alternative has superior efficacy. Listeria is intrinsically resistant to cephalosporins — ⛔ Never use cephalosporins alone if Listeria is suspected.
When NOT to use: Known penicillin/ampicillin allergy (anaphylaxis-type). In severe penicillin allergy, co-trimoxazole (TMP-SMX) IV is the alternative. Meropenem may also be considered.
NLEM India: Ampicillin injection is included in NLEM India (2022 edition).
Time to expected clinical response: Clinical improvement (defervescence, improved sensorium) expected within 48–72 hours. CSF sterilisation typically occurs within 48–96 hours.
Criteria for treatment failure: Persistent fever >72 hours, worsening sensorium, repeat CSF showing no improvement in cell count/protein/culture. Consider: inadequate dosing, drug resistance (extremely rare for Listeria), alternative diagnosis, or secondary complication (abscess, hydrocephalus, ventriculitis).
Mandatory baseline investigations: Blood cultures (×2 sets), CSF analysis (cell count, protein, glucose, Gram stain, culture, India ink/crypto antigen if immunocompromised), serum creatinine/eGFR, complete blood count.
Specialist initiation: ⚠️ Requires specialist supervision (Infectious Disease / Internal Medicine / Neurology). ICU admission recommended for all cases of bacterial meningitis.
Indian guideline source: API Textbook of Medicine — Chapter on Bacterial Meningitis; AIIMS Infectious Disease protocol; ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019).
Key disease-specific safety warning: ⚠️ Do NOT reduce dose or frequency even if patient appears to improve rapidly. Subtherapeutic CSF levels lead to relapse. Ensure q4h dosing is strictly maintained round the clock.
Common dose adjustment scenarios: Renal impairment — extend interval (see Renal Adjustment section). No hepatic dose adjustment needed.

2. Bacterial Meningitis — Empirical Therapy (As part of combination regimen)

Context: In empirical meningitis management, ampicillin is added to cephalosporin-based regimens specifically to cover Listeria in at-risk populations.

Route	Standard Dose	Maximum Dose	Clinical Notes
IV	2 g IV every 4 hours	Max 2 g per dose; Max 12 g per day	Added to Ceftriaxone 2 g IV q12h (or Cefotaxime 2 g IV q4-6h) + Dexamethasone

Who needs empirical Listeria coverage (add ampicillin):

Age >50 years
Neonates and infants <3 months (see Paediatric section)
Pregnant women
Immunocompromised (HIV, organ transplant, chronic steroids, malignancy)
Alcoholism, chronic liver disease
Diabetes mellitus (relative indication)

Who does NOT need ampicillin added:

Immunocompetent adults aged 18–50 years with no risk factors — standard empirical therapy is ceftriaxone + dexamethasone ± vancomycin (for suspected resistant Pneumococcus).

Duration: If Listeria is excluded on cultures, ampicillin can be discontinued. Total empirical duration until culture results: typically 48–72 hours for the “Listeria cover” component.

Indian guideline source: API Textbook of Medicine; AIIMS Infectious Disease Protocol.

3. Infective Endocarditis — Enterococcus faecalis

Context: Ampicillin is the cornerstone drug in treating Enterococcus faecalis endocarditis (the most common Enterococcal species causing IE in India, and usually ampicillin-susceptible). Two standard combination regimens are used:

Regimen A — Ampicillin + Gentamicin (traditional):

Route	Standard Dose	Maximum Dose	Duration	Clinical Notes
IV (ampicillin)	2 g IV every 4 hours	Max 2 g per dose; Max 12 g per day	4–6 weeks (6 weeks for prosthetic valve IE)	Continuous IV access (PICC line recommended for prolonged therapy)
IV (gentamicin — synergy dose)	1 mg/kg IV every 8 hours	Guided by TDM (trough <1 mcg/mL)	2–6 weeks (monitor renal function weekly)	⚠️ Nephrotoxicity and ototoxicity risk — requires TDM and weekly creatinine

Regimen B — Ampicillin + Ceftriaxone (aminoglycoside-sparing — preferred in renal impairment):

Route	Standard Dose	Maximum Dose	Duration	Clinical Notes
IV (ampicillin)	2 g IV every 4 hours	Max 2 g per dose; Max 12 g per day	6 weeks	Round-the-clock q4h dosing essential
IV (ceftriaxone)	2 g IV every 12 hours	Max 4 g per day	6 weeks	Synergistic by double cell-wall targeting. Avoids aminoglycoside toxicity.

💡 Clinical pearl: The ampicillin + ceftriaxone regimen for Enterococcal IE has strong evidence (multiple studies including the POET trial principles) and is increasingly preferred over the traditional ampicillin + gentamicin regimen, especially in patients with renal impairment or when prolonged aminoglycoside use is risky. Note: this synergy is specific to E. faecalis and does NOT apply to E. faecium.

Mandatory Clinical Notes Checklist:

When to prefer: Ampicillin is first-line for ampicillin-susceptible E. faecalis IE (which is the majority of E. faecalis in India). Regimen B (ampicillin + ceftriaxone) is preferred when renal function is compromised or there are concerns about aminoglycoside toxicity.
When NOT to use: ⛔ Do not use for E. faecium endocarditis (usually ampicillin-resistant — requires vancomycin or daptomycin-based regimen). Do not use for HACEK or staphylococcal IE.
NLEM India: Ampicillin injection — included in NLEM India (2022).
Time to expected clinical response: Blood culture clearance expected within 3–5 days. Defervescence within 5–7 days.
Criteria for treatment failure: Persistent positive blood cultures >7 days despite appropriate therapy, persistent fever >10 days, new embolic events, worsening heart failure, echocardiographic evidence of worsening vegetation or abscess. Consider surgical evaluation.
Mandatory baseline investigations: ⚠️ At least 3 sets of blood cultures (from different venepuncture sites, ideally before starting antibiotics). Echocardiography (TTE initially; TEE if prosthetic valve or poor TTE windows). Serum creatinine, eGFR, complete blood count, inflammatory markers (ESR, CRP). Hearing assessment if aminoglycoside planned.
Specialist initiation: ⚠️ Mandatory specialist management — Infectious Disease, Cardiology, and/or Cardiothoracic Surgery team involvement. Managed as an inpatient or via OPAT (Outpatient Parenteral Antibiotic Therapy) in select centres.
Indian guideline source: API Textbook of Medicine — Infective Endocarditis chapter; AIIMS Cardiology and Infectious Disease protocols; also aligns with AHA/ESC guidelines adapted for Indian organisms and susceptibility patterns.
Key disease-specific safety warning: ⚠️ Monitor renal function weekly if using gentamicin combination. Immediate gentamicin TDM and discontinuation if trough exceeds target. Switch to Regimen B if renal function deteriorates. ⚠️ Do not use oral step-down for enterococcal IE — IV therapy for the full duration is standard.
Common dose adjustment scenarios: Renal impairment — use Regimen B (ampicillin + ceftriaxone). Extend ampicillin dosing interval if eGFR significantly reduced (see Renal Adjustment).

4. Infective Endocarditis Prophylaxis — Pre-procedural

Context: For patients with high-risk cardiac conditions undergoing dental or other invasive procedures, ampicillin IV/IM is used when the patient cannot take oral medication (amoxicillin 2 g oral is preferred when the patient can take oral drugs).

Route	Dose	Timing	Maximum Dose	Clinical Notes
IV or IM	2 g as a single dose	30–60 minutes before the procedure (preferred timing: 30 min before)	Single dose of 2 g	Only for patients who cannot take oral amoxicillin.

Who qualifies for IE prophylaxis (high-risk cardiac conditions):

Prosthetic heart valves (mechanical or bioprosthetic)
Previous infective endocarditis
Congenital heart disease (unrepaired cyanotic, repaired with prosthetic material within 6 months, repaired with residual defects adjacent to prosthetic material)
Cardiac transplant recipients with valvulopathy
Rheumatic heart disease with significant valvular lesions (relevant in India — high RHD burden)

ℹ️ In India, rheumatic heart disease (RHD) remains a common high-risk condition for IE. Prophylaxis is particularly relevant before dental procedures involving gingival manipulation, periapical procedures, or perforation of oral mucosa.

When to prefer ampicillin IV/IM over oral amoxicillin: Patient is nil per oral (pre-operative), vomiting, unable to swallow, or unreliable oral absorption. Otherwise, amoxicillin 2 g oral is equally effective and preferred.

Penicillin allergy: If non-anaphylactic penicillin allergy → use clindamycin 600 mg IV/oral or azithromycin 500 mg oral. If anaphylactic penicillin allergy → ⛔ avoid all penicillins including ampicillin. Use clindamycin 600 mg IV.

Indian guideline source: API Textbook of Medicine; adapted from AHA prophylaxis guidelines with Indian RHD context.

5. Intrapartum Group B Streptococcus (GBS) Prophylaxis

Context: Ampicillin IV is a recommended alternative to penicillin G for intrapartum GBS prophylaxis. Penicillin G is the preferred agent (narrower spectrum), but ampicillin is acceptable and often used when penicillin G is unavailable.

Route	Loading Dose	Maintenance Dose	Maximum Dose	Duration	Clinical Notes
IV	2 g IV stat at onset of labour or rupture of membranes	1 g IV every 4 hours	Max 1 g per dose (maintenance); Max loading 2 g	Until delivery	⚠️ Adequate prophylaxis = at least one full dose given ≥4 hours before delivery.

Who needs intrapartum GBS prophylaxis:

Positive GBS rectovaginal culture at 35–37 weeks gestation
GBS bacteriuria during current pregnancy
Previous infant with invasive GBS disease
Unknown GBS status PLUS any of: preterm labour <37 weeks, prolonged rupture of membranes ≥18 hours, intrapartum fever ≥38°C

Mandatory Clinical Notes Checklist (abbreviated for prophylaxis):

When to prefer ampicillin: When penicillin G is unavailable (which is common in many Indian hospitals — penicillin G injection shortage is frequent). Ampicillin is the standard alternative.
When NOT to use: Penicillin allergy with anaphylaxis history → use clindamycin 900 mg IV q8h (if GBS susceptible) or vancomycin 20 mg/kg IV q8h (max 2 g per dose) if susceptibility unknown.
NLEM India: Ampicillin injection — included in NLEM India (2022).
Expected response: Prophylaxis — no “response” expected. Adequacy defined by at least one dose ≥4 hours before delivery. Neonatal GBS risk reduction: >80% with adequate prophylaxis.
Key safety warning: ⚠️ This is a prophylactic indication. Do NOT wait for culture results if risk factors present and delivery is imminent. Start prophylaxis immediately when indicated.
Indian guideline source: FOGSI (Federation of Obstetric and Gynaecological Societies of India) guidelines; API Textbook — Obstetric Infections; ICMR AMR guidelines (supportive).

6. Community-Acquired Pneumonia (CAP) — Moderate to Severe (Hospitalised)

Context: IV ampicillin is used as part of combination empirical therapy for hospitalised CAP when atypical coverage is also provided. For non-severe CAP managed as outpatient, oral amoxicillin (not ampicillin) is preferred due to superior bioavailability. IV ampicillin covers S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains), and other susceptible respiratory pathogens.

Route	Starting Dose	Titration	Maintenance	Maximum Dose	Clinical Notes
IV	1–2 g IV q6h	Not applicable	1–2 g IV every 6 hours	Max 2 g per dose; Max 8–12 g per day	Usually combined with a macrolide (azithromycin 500 mg IV/oral OD) for atypical coverage
Oral (step-down)	500 mg oral q6h	Not applicable	500 mg oral every 6 hours	Max 500 mg per dose (oral); Max 2 g per day (oral route limitation)	Switch to oral after clinical improvement. Oral amoxicillin 500 mg–1 g q8h is preferred over oral ampicillin for step-down due to better bioavailability.

Duration: Total 5–7 days (may be shorter with clinical and CRP-guided protocols; extend to 10–14 days for complicated/necrotising pneumonia or empyema).

Mandatory Clinical Notes Checklist:

When to prefer ampicillin: In Indian district hospitals or settings where IV amoxicillin-clavulanate or ceftriaxone may not be available. Ampicillin IV is a reasonable empirical option for non-severe hospitalised CAP, especially if local antibiogram shows reasonable S. pneumoniae susceptibility. Also appropriate as definitive therapy when S. pneumoniae is confirmed susceptible.
When NOT to use: ⚠️ Do NOT use as monotherapy — must be combined with macrolide or fluoroquinolone for atypical coverage. Do NOT use if beta-lactamase-producing H. influenzae is likely (use amoxicillin-clavulanate or cephalosporin). Do NOT use for severe CAP requiring ICU (use ceftriaxone/cefotaxime + macrolide/fluoroquinolone per API/ICMR guidelines). Do NOT use for hospital-acquired or ventilator-associated pneumonia.
NLEM India: Ampicillin injection — included in NLEM India (2022). Amoxicillin is the preferred oral aminopenicillin in NLEM.
Time to expected clinical response: Defervescence and clinical improvement within 48–72 hours.
Treatment failure criteria: Persistent or worsening fever at 72 hours, worsening hypoxia, radiographic progression, new organ dysfunction. Broaden coverage, obtain sputum/blood cultures, consider resistant organisms, alternative diagnoses (TB, fungal, viral), or complications (empyema, abscess).
Mandatory baseline investigations: Chest X-ray, SpO₂/ABG, blood cultures (×2 before antibiotics), complete blood count, serum creatinine, CRP or PCT (if available). Sputum Gram stain and culture (if obtainable).
Specialist initiation: Not required for general hospitalised CAP — can be initiated by any treating physician.
Indian guideline source: ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019); API Textbook — Community-Acquired Pneumonia chapter.
Key safety warning: ℹ️ In areas with high beta-lactamase-producing H. influenzae prevalence, consider amoxicillin-clavulanate or ceftriaxone as first-line rather than ampicillin alone.
Common dose adjustment scenarios: Renal impairment — adjust interval. Elderly — dose based on eGFR.

7. Urinary Tract Infections (UTI) — When Susceptibility Confirmed

⚠️ Critical India-Specific Warning: Empirical use of ampicillin for UTI is NOT recommended in India due to extremely high resistance rates among uropathogens (>70–90% of E. coli and Klebsiella are ampicillin-resistant in most Indian institutional antibiograms). Use ONLY when culture and sensitivity confirms susceptibility. For empirical UTI therapy, refer to nitrofurantoin (uncomplicated) or cephalosporins/fluoroquinolones (as per local antibiogram and ICMR AMR guidelines).

Route	Dose	Maximum Dose	Duration	Clinical Notes
Oral	500 mg q6h	Max 500 mg per dose; Max 2 g per day	Uncomplicated UTI: 3–7 days (women), 7 days (men)	Only when susceptibility confirmed. Take on empty stomach.
IV	1–2 g q6h	Max 2 g per dose; Max 8 g per day	Complicated UTI / Pyelonephritis: 10–14 days (total IV + oral step-down)	Switch to oral when afebrile for 48 hours and clinically improving.

Mandatory Clinical Notes Checklist:

When to prefer: ONLY after susceptibility confirmation. Particularly relevant for E. faecalis UTI (intrinsically ampicillin-susceptible, often resistant to cephalosporins) — ampicillin is the drug of choice for Enterococcal UTI. Also useful for susceptible Proteus mirabilis UTI.
When NOT to use: ⛔ Do NOT use empirically for UTI in India. Do NOT use for catheter-associated UTI without susceptibility data. Do NOT use for recurrent UTI prophylaxis.
NLEM India: Ampicillin — yes, included. However, ICMR AMR guidelines do NOT recommend empirical ampicillin for UTI in India.
Time to expected clinical response: Symptom improvement within 48–72 hours. If no improvement, reassess susceptibility and consider alternative.
Treatment failure criteria: Persistent symptoms at 72 hours, positive repeat culture, relapse within 2 weeks.
Mandatory baseline investigations: Urine culture and sensitivity (MANDATORY before starting ampicillin for UTI). Serum creatinine, complete blood count. Imaging (USG KUB) for complicated UTI or pyelonephritis.
Specialist initiation: Not required — can be prescribed by any physician once susceptibility is confirmed.
Indian guideline source: ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019) — specifically recommends culture-directed therapy when aminopenicillins are considered for UTI.
Key safety warning: ℹ️ Do not assume susceptibility even if the organism is E. coli — always check the individual isolate’s susceptibility.
Dose adjustment: Renal impairment — extend dosing interval (see Renal Adjustment).

8. Enteric Fever (Typhoid / Paratyphoid) — Susceptibility-Confirmed Cases

⚠️ Critical India-Specific Warning: Multi-drug resistant (MDR) Salmonella typhi (resistant to ampicillin, chloramphenicol, and co-trimoxazole) is highly prevalent in India (>50–60% in many regions). Empirical first-line for enteric fever in India is ceftriaxone (parenteral) or azithromycin (oral, mild cases). Ampicillin is reserved for susceptibility-confirmed cases only, particularly fully susceptible strains.

Route	Dose	Maximum Dose	Duration	Clinical Notes
Oral	750 mg–1 g q6h	Max 1 g per dose; Max 4 g per day	14 days (uncomplicated)	Only when susceptibility confirmed. Take on empty stomach.
IV	1–2 g q6h	Max 2 g per dose; Max 8–12 g per day	14 days (or until afebrile × 5 days, then switch to oral)	For severe/complicated typhoid (toxicity, peritonitis, perforation)

ℹ️ Condition-specific note: Typhoid perforation with peritonitis requires surgical management + IV ampicillin (or ampicillin-sulbactam) with an aminoglycoside and metronidazole as part of a combination regimen.

Mandatory Clinical Notes Checklist (abbreviated):

When to prefer: Only for fully susceptible S. typhi or S. paratyphi (ampicillin MIC ≤ 2 mcg/mL). May be cost-effective in susceptible cases compared to ceftriaxone or azithromycin.
When NOT to use: ⛔ Do NOT use empirically. MDR and fluoroquinolone-resistant typhoid is common in India — wait for susceptibility. Do NOT use for chronic carriers (oral amoxicillin or ciprofloxacin are preferred for carrier eradication).
NLEM India: Yes — ampicillin is included.
Time to expected clinical response: Defervescence expected within 3–5 days of appropriate therapy (may take up to 7 days). Slow clinical response is expected with Salmonella.
Indian guideline source: ICMR AMR guidelines (2019); API Textbook — Enteric Fever chapter.

9. Sepsis / Bacteraemia — Specific Organisms

Ampicillin IV is used as targeted therapy for bacteraemia caused by:

Enterococcus faecalis — ampicillin is first-line
Listeria monocytogenes — ampicillin is first-line (often + gentamicin)

Route	Dose	Maximum Dose	Duration	Clinical Notes
IV	2 g IV every 4–6 hours	Max 2 g per dose; Max 12 g per day	Enterococcal bacteraemia: 2–4 weeks (shorter if uncomplicated, no endocarditis, removable source). Listeria bacteraemia: 14–21 days.	Always assess for endocarditis in Enterococcal bacteraemia (echocardiography recommended)

ℹ️ Empirical neonatal sepsis (ampicillin + gentamicin) is covered under Paediatric Dosing (Part 3).

💡 Indian context: Enterococcal bacteraemia is frequently encountered in post-operative and catheter-related infections in Indian hospitals. Always obtain blood cultures before starting and check ampicillin susceptibility — VRE rates are rising in tertiary care centres.

10. Intra-abdominal Infections — Peritonitis, Cholangitis (Combination Therapy)

Context: Ampicillin provides Enterococcal and Streptococcal coverage in polymicrobial intra-abdominal infections. Always used in combination with:

Metronidazole (for anaerobic coverage) AND
Gentamicin or a third-generation cephalosporin (for Gram-negative coverage)

This is the classic “triple regimen” (ampicillin + gentamicin + metronidazole) widely used in Indian surgical practice.

Route	Dose	Maximum Dose	Duration	Clinical Notes
IV	1–2 g IV every 6 hours	Max 2 g per dose; Max 8 g per day	4–7 days post source control (shorter if adequate surgical source control achieved)	Always used in combination. Monotherapy with ampicillin is inadequate for intra-abdominal infections.

Mandatory Clinical Notes (abbreviated):

When to prefer ampicillin in this context: When Enterococcal coverage is specifically needed (post-operative peritonitis, biliary infections, hepatobiliary surgery, liver transplant). In community-acquired, non-complicated appendicitis or cholecystitis managed surgically, Enterococcal coverage is generally NOT needed.
When NOT to use: ⛔ Not as monotherapy. Not for hospital-acquired intra-abdominal infections with suspected resistant Gram-negatives — use piperacillin-tazobactam or carbapenem-based regimens.
Indian guideline source: API Textbook — Peritonitis chapter; AIIMS Surgical Infectious Disease protocols.
Key safety warning: ⚠️ Monitor renal function closely when combining ampicillin with gentamicin, especially in post-operative patients who may have fluctuating renal function.

11. Skin and Soft Tissue Infections — Susceptibility-Confirmed, Non-Staphylococcal

Route	Dose	Maximum Dose	Duration	Clinical Notes
Oral	250–500 mg q6h	Max 500 mg per dose; Max 2 g per day	5–7 days (uncomplicated)	Primarily for Streptococcal cellulitis, erysipelas when susceptibility known
IV	1–2 g q6h	Max 2 g per dose; Max 8 g per day	7–14 days (complicated/deep SSTI)	For severe cellulitis, necrotising fasciitis (as part of combination regimen)

ℹ️ Limited role: For most skin and soft tissue infections in India, amoxicillin-clavulanate (oral) or cephalosporins are preferred due to better coverage of S. aureus (beta-lactamase producing). Ampicillin alone does NOT cover methicillin-susceptible S. aureus (MSSA) — most MSSA produces beta-lactamase. Use only for Streptococcal infections or when susceptibility confirmed. For combined Gram-positive + Gram-negative coverage, ampicillin-cloxacillin combination capsules are used in Indian practice.

12. Respiratory Tract Infections — Upper (Pharyngitis, Sinusitis, Otitis Media)

Route	Dose	Maximum Dose	Duration	Clinical Notes
Oral	250–500 mg q6h	Max 500 mg per dose; Max 2 g per day	Pharyngitis (GAS): 10 days. Sinusitis: 7–10 days. Otitis media: 7–10 days.	⚠️ Oral amoxicillin is preferred over oral ampicillin for all these indications (better bioavailability, simpler dosing q8h). Use ampicillin only if amoxicillin is unavailable.

ℹ️ Condition-specific notes:

GAS Pharyngitis: Penicillin V or amoxicillin are first-line. Ampicillin is a second-line oral option. Confirm GAS by rapid antigen test or throat culture before prescribing antibiotics. Treating GAS pharyngitis prevents acute rheumatic fever — very relevant in India.
Acute Otitis Media (AOM): Amoxicillin is first-line. Ampicillin is an alternative if amoxicillin is unavailable. Most paediatric AOM is managed with amoxicillin (see Paediatric section).
Acute Bacterial Sinusitis: Amoxicillin or amoxicillin-clavulanate preferred. Ampicillin oral is a second-line option.

Secondary Indications — Adults Only (Off-label, if any)

1. Spontaneous Bacterial Peritonitis (SBP) — Treatment

OFF-LABEL but accepted standard practice in India

Context: Ampicillin-sulbactam (not ampicillin alone) is used as an alternative empirical regimen for SBP in cirrhotic patients, particularly in settings where cephalosporin resistance is a concern. Ampicillin alone is inadequate due to Gram-negative resistance. However, ampicillin IV (without sulbactam) may be used as part of a combination regimen for culture-confirmed, susceptible SBP organisms.

Route	Dose	Maximum Dose	Duration	Clinical Notes
IV (ampicillin)	1–2 g IV q6h	Max 2 g per dose; Max 8 g per day	5 days (7 days if slow clinical response)	Only for susceptibility-confirmed organisms. Otherwise, use ceftriaxone or ampicillin-sulbactam empirically.

Evidence quality: Moderate (observational data, expert consensus in Indian hepatology practice)
Indian source: API Textbook — Hepatology section; AIIMS Hepatology protocol
Clearly marked: OFF-LABEL but accepted standard practice in India

2. Chorioamnionitis / Intra-amniotic Infection — Treatment

OFF-LABEL but accepted standard practice in India

Context: Ampicillin IV is a key component of the standard regimen for intrapartum chorioamnionitis: Ampicillin + Gentamicin ± Metronidazole/Clindamycin (for anaerobic coverage if caesarean delivery anticipated).

Route	Dose	Maximum Dose	Duration	Clinical Notes
IV (ampicillin)	2 g IV stat, then 1 g IV q4–6h	Max 2 g per dose (loading); Max 6–8 g per day	Until delivery + one additional dose post-delivery (if vaginal delivery). If caesarean section: continue 24–48 hours post-operatively.	Combined with gentamicin 1.5 mg/kg IV q8h (or 5 mg/kg IV once daily). Add clindamycin/metronidazole if caesarean section performed.

Evidence quality: Strong (established obstetric practice, multiple observational studies)
Indian source: FOGSI guidelines; API Textbook — Obstetric Infections
Clearly marked: OFF-LABEL but accepted standard practice in India

3. Post-Partum Endometritis — Treatment (Combination Regimen)

OFF-LABEL but accepted standard practice in India

Route	Dose	Maximum Dose	Duration	Clinical Notes
IV (ampicillin)	2 g IV q6h	Max 2 g per dose; Max 8 g per day	Until afebrile for 24–48 hours, then switch to oral	Triple regimen: Ampicillin + Gentamicin + Clindamycin (or Metronidazole). “Gentamicin-clindamycin” or “ampicillin-gentamicin-clindamycin” are both standard regimens.

Evidence quality: Strong (established standard of care in obstetric practice)
Indian source: FOGSI guidelines; AIIMS Obstetrics protocols
Clearly marked: OFF-LABEL but accepted standard practice in India

4. PPROM (Preterm Premature Rupture of Membranes) — Latency Antibiotic Regimen

OFF-LABEL but accepted standard practice in India

Context: Antibiotics to prolong latency (delay delivery) in PPROM. The standard Mercer regimen includes ampicillin + erythromycin.

Route	Dose	Maximum Dose	Duration	Clinical Notes
IV (ampicillin)	2 g IV q6h	Max 2 g per dose; Max 8 g per day	48 hours IV, then switch to oral amoxicillin 250 mg q8h for 5 days	Combined with erythromycin 250 mg IV q6h × 48 hours, then erythromycin 333 mg oral q8h × 5 days

Evidence quality: Strong (Mercer RCT, ORACLE trial; endorsed by multiple obstetric guidelines)
Indian source: FOGSI PPROM guidelines; API Textbook — Obstetric Complications
⛔ Do NOT use amoxicillin-clavulanate for PPROM latency antibiotics — associated with increased risk of neonatal necrotising enterocolitis (ORACLE II trial).
Clearly marked: OFF-LABEL but accepted standard practice in India

5. Whipple’s Disease (Tropheryma whipplei)

OFF-LABEL

Route	Dose	Maximum Dose	Duration	Clinical Notes
IV (ampicillin)	2 g IV q4–6h	Max 2 g per dose; Max 12 g per day	14 days induction IV, then switch to oral co-trimoxazole (TMP-SMX DS) for 12 months maintenance	Extremely rare in India. Specialist (Gastroenterology/Infectious Disease) supervision mandatory.

Evidence quality: Weak (case series, expert consensus — disease extremely rare)
Clearly marked: OFF-LABEL
Specialist only

PAEDIATRIC DOSING (Specialist Only)

General Notes:

⚠️ Safety monitoring: Monitor for hypersensitivity reactions (rash, urticaria, anaphylaxis) — especially with first dose. Monitor for antibiotic-associated diarrhoea and Clostridioides difficile infection in prolonged courses. Monitor renal function (serum creatinine) in neonates and children receiving high-dose IV therapy.
Minimum age: Ampicillin is approved and used from birth (including preterm neonates) — no minimum age restriction.
Minimum weight: No minimum weight restriction — dosing is weight-based. Neonatal doses are further stratified by gestational age and postnatal age.
Formulation suitability for children:
- ✔ Oral suspension (125 mg/5 mL, 250 mg/5 mL) — suitable for infants and young children. Requires reconstitution with water before use.
- ⚠️ Palatability: Ampicillin suspension has a mildly bitter taste that some children find unpalatable. Can be mixed with a small amount of water or juice immediately before administration. Do NOT pre-mix with milk or formula (may reduce stability and absorption). Flavoured commercial preparations are available from some Indian manufacturers.
- ✔ Capsules (250 mg, 500 mg) — can be used in older children/adolescents who can swallow capsules. Capsules should NOT be opened and mixed with food — bioavailability data for opened capsule contents is limited.
- ✔ Injection (250 mg, 500 mg, 1 g vials) — suitable for all ages including neonates.
Age-specific pharmacokinetic differences:
- Neonates (preterm and term): Significantly prolonged half-life (4–6 hours in preterm, 2–4 hours in term neonates) due to immature renal function and larger Vd per kg. Requires extended dosing intervals (q8h or q12h depending on gestational and postnatal age).
- Infants and children (>1 month to 12 years): Weight-adjusted clearance approaches adult values by 1 month of age. Standard q6h dosing interval used. May require higher mg/kg doses than adults due to larger Vd per kg and faster renal clearance per kg.
- Adolescents (≥12 years or ≥40 kg): Use adult dosing.

NEONATAL DOSING

⚠️ Neonatal use — NICU supervision only

Ampicillin is one of the most commonly used antibiotics in neonatal medicine worldwide and in India. It is a component of the standard empirical neonatal sepsis regimen (Ampicillin + Gentamicin) recommended by WHO, NNF (National Neonatology Forum of India), and IAP.

Neonatal Dosing Table — by Gestational Age (GA) and Postnatal Age (PNA):

Indication	GA / PNA	Dose	Interval	Route	Maximum Daily Dose	Notes
Early-onset neonatal sepsis (EONS) — Empirical	≤34 weeks GA, PNA 0–7 days	50 mg/kg/dose	Every 12 hours (q12h)	IV (preferred) or IM	100 mg/kg/day	Combined with Gentamicin. IV route strongly preferred.
	≤34 weeks GA, PNA 8–28 days	50 mg/kg/dose	Every 8 hours (q8h)	IV or IM	150 mg/kg/day
	≥35 weeks GA, PNA 0–7 days	50 mg/kg/dose	Every 8 hours (q8h)	IV or IM	150 mg/kg/day
	≥35 weeks GA, PNA 8–28 days	50 mg/kg/dose	Every 6 hours (q6h)	IV or IM	200 mg/kg/day
Late-onset neonatal sepsis (LONS) — Empirical	All neonates >72 hours of life	50 mg/kg/dose	Every 6–8 hours (based on GA/PNA as above)	IV	As above	Combined with Gentamicin (or Amikacin if local resistance pattern warrants). Consider adding cefotaxime if Gram-negative meningitis suspected.
Neonatal meningitis	≤34 weeks GA	100 mg/kg/dose	Every 12 hours (q12h) for PNA 0–7 days; Every 8 hours (q8h) for PNA >7 days	IV only	200–300 mg/kg/day	Higher doses needed for CSF penetration. Combined with Gentamicin ± Cefotaxime.
	≥35 weeks GA	100 mg/kg/dose	Every 8 hours (q8h) for PNA 0–7 days; Every 6 hours (q6h) for PNA >7 days	IV only	300–400 mg/kg/day
GBS sepsis/meningitis (confirmed)	All neonates	50–100 mg/kg/dose (100 mg/kg for meningitis)	As per GA/PNA intervals above	IV only	200–400 mg/kg/day	Duration: Sepsis without meningitis 10 days. Meningitis: 14–21 days.
Listeria neonatal infection	All neonates	50–100 mg/kg/dose	As per GA/PNA intervals above	IV only	200–400 mg/kg/day	Combined with Gentamicin for synergy. Duration: 14–21 days (meningitis: 21 days).

Neonatal-Specific Clinical Notes:

⚠️ Ampicillin + Gentamicin is the WHO-recommended and NNF India-recommended first-line empirical regimen for both EONS and LONS. This combination provides synergistic activity against GBS, Listeria, E. coli (susceptible strains), and Enterococcus.
⚠️ EONS vs LONS distinction: EONS (onset within first 72 hours of life) — typically vertical transmission from maternal flora (GBS, E. coli, Listeria). LONS (onset after 72 hours) — may include nosocomial organisms. In Indian NICUs with high rates of Gram-negative resistance, LONS empirical therapy may need modification (e.g., ampicillin + amikacin, or ampicillin + cefotaxime) based on unit-specific antibiogram. Always refer to local NICU antibiogram.
ℹ️ IV administration in neonates: Administer by slow IV injection over 3–5 minutes or by IV infusion over 15–30 minutes. Never give by rapid IV push in neonates — risk of seizures with very rapid infusion of high concentrations.
ℹ️ IM route in neonates: Acceptable when IV access is not available (e.g., in resource-limited settings, peripheral health centres before transfer). Use the anterolateral thigh as the injection site. Maximum volume per IM injection site in neonates: 0.5 mL.
Duration of empirical therapy: If blood cultures are negative at 36–48 hours and clinical suspicion is low, discontinue ampicillin + gentamicin. ⚠️ Do NOT continue empirical antibiotics beyond 48–72 hours in culture-negative, clinically well neonates — prolonged empirical antibiotics in neonates are associated with increased risk of NEC, invasive fungal infection, and death (evidence from multiple neonatal studies).
Indian guideline source: NNF (National Neonatology Forum) Clinical Practice Guidelines — Neonatal Sepsis (latest edition); IAP Neonatology Chapter guidelines; WHO Pocket Book of Hospital Care for Children; ICMR AMR guidelines (2019).

Primary Indications — Paediatric (Approved / Standard in India)

1. Neonatal Sepsis — Empirical (EONS and LONS)

(Dosing covered in Neonatal Dosing Table above)

Mandatory Clinical Notes Checklist (Paediatric-adapted):

When to prefer: First-line empirical therapy for suspected neonatal sepsis (both EONS and LONS) as part of ampicillin + gentamicin combination. No alternative regimen is superior for EONS in most settings.
When NOT to use: ⛔ Do NOT use ampicillin monotherapy for neonatal sepsis — always combine with gentamicin (and/or cefotaxime for meningitis). In NICU settings with very high Gram-negative resistance (ESBL/CRE prevalence), the empirical regimen may need modification — this is a unit-level decision guided by the local antibiogram.
NLEM India: Ampicillin injection — included in NLEM India (2022).
Time to expected clinical response: Clinical improvement (reduction in apnoea, feeding improvement, normalisation of temperature instability) within 48–72 hours. Blood culture positivity usually results within 24–48 hours.
Treatment failure criteria: Persistent clinical deterioration at 48–72 hours, persistent positive blood cultures, development of new foci (meningitis, osteomyelitis, NEC). Escalate antibiotics based on culture results and local resistance patterns.
Mandatory baseline investigations: Blood culture (MANDATORY — at least 1 mL in paediatric blood culture bottle, preferably before antibiotics), complete blood count with differential, CRP (serial — at 0 and 24–48 hours), blood glucose, serum electrolytes. Lumbar puncture for CSF analysis (cell count, protein, glucose, Gram stain, culture) — recommended for all suspected LONS and when meningitis is clinically suspected. May be deferred in unstable neonates but should be done as soon as clinically feasible.
Specialist initiation: ⚠️ NICU/paediatrician supervision mandatory. In resource-limited peripheral settings, initial dose of ampicillin + gentamicin IM can be given by trained medical officers before referral (as per IMNCI/WHO guidelines).
Indian guideline source: NNF Clinical Practice Guidelines — Neonatal Sepsis; IAP Neonatology Chapter; WHO IMNCI guidelines; ICMR AMR guidelines.
Key safety warning: ⚠️ Ampicillin sodium injection contains sodium — relevant in fluid-restricted preterm neonates. 1 g ampicillin sodium provides ~66.7 mg (2.9 mEq) of sodium. Factor into total sodium intake calculations.
Common dose adjustment scenarios: Preterm neonates require extended dosing intervals (q12h) due to immature renal function. Renal impairment in neonates (e.g., perinatal asphyxia-related AKI) — further extend intervals; monitor serum creatinine.

2. Neonatal Meningitis

(Dosing covered in Neonatal Dosing Table above)

ℹ️ Key additional note: Higher doses (100 mg/kg/dose) are essential for meningitis to achieve adequate CSF concentrations. Standard sepsis doses (50 mg/kg/dose) are insufficient for meningitis.

Duration:

GBS meningitis: 14–21 days (minimum 14 days from first sterile CSF culture)
Listeria meningitis: 21 days minimum
Gram-negative meningitis: 21 days minimum (often requires cefotaxime or meropenem as primary agent; ampicillin provides supplementary coverage)

Repeat lumbar puncture: Recommended at 48–72 hours to document CSF sterilisation, especially for Gram-negative meningitis. End-of-treatment LP also recommended.

3. Paediatric Community-Acquired Pneumonia (CAP) — Hospitalised, Non-severe to Moderate

Weight-based dosing table:

Age Group	Route	Dose	Interval	Max Daily Dose	Duration	Notes
1 month – 12 years	IV	50 mg/kg/dose	Every 6 hours (q6h)	200 mg/kg/day (max absolute: 8 g/day)	5–7 days total (IV + oral step-down)	For hospitalised children requiring parenteral antibiotics
1 month – 12 years	Oral (step-down or mild cases)	25–50 mg/kg/dose	Every 6 hours (q6h)	100–200 mg/kg/day (max absolute: 2 g/day)	5–7 days total	Oral amoxicillin is preferred over oral ampicillin — use ampicillin only if amoxicillin unavailable
≥12 years or ≥40 kg	Use adult dosing	—	—	—	—	—

Mandatory Clinical Notes:

When to prefer: IV ampicillin for hospitalised paediatric CAP when S. pneumoniae is the likely pathogen. IAP recommends IV ampicillin or IV amoxicillin as first-line for non-severe hospitalised CAP in children.
When NOT to use: ⛔ Not for severe CAP requiring ICU (use ceftriaxone/cefotaxime). Not for suspected staphylococcal pneumonia (complicated pneumonia with empyema/pneumatocoeles — use cloxacillin/vancomycin). Not adequate for suspected atypical pneumonia in older children (add macrolide).
NLEM India: Yes.
Expected response: Defervescence and respiratory improvement within 48–72 hours.
Indian guideline source: IAP Guidelines on Management of CAP in Children (revised 2021); WHO Pocket Book of Hospital Care for Children; ICMR guidelines.

4. Paediatric Urinary Tract Infection (UTI) — Susceptibility-Confirmed

⚠️ Same resistance caution as adults — do NOT use empirically for paediatric UTI in India.

Age Group	Route	Dose	Interval	Max Daily Dose	Duration	Notes
1 month – 12 years	IV (febrile UTI / pyelonephritis)	50 mg/kg/dose	Every 6 hours (q6h)	200 mg/kg/day (max absolute: 8 g/day)	10–14 days total (IV followed by oral step-down)	Only when susceptibility confirmed. Common for Enterococcus faecalis UTI.
1 month – 12 years	Oral (afebrile / lower UTI)	25–50 mg/kg/dose	Every 6 hours (q6h)	100 mg/kg/day (max absolute: 2 g/day)	7 days	Only when susceptibility confirmed.
≥12 years or ≥40 kg	Use adult dosing	—	—	—	—	—

Mandatory baseline: Urine culture and sensitivity (MANDATORY). Renal ultrasound for febrile UTI in children (to exclude obstruction, renal abscess, vesicoureteral reflux).

Indian guideline source: IAP Guidelines on UTI in Children; Indian Paediatric Nephrology Group (IPNG) guidelines.

5. Paediatric Bacterial Meningitis — Beyond Neonatal Period (1 month to 12 years)

Context: In children >1 month, ampicillin is NOT the primary drug for empirical meningitis (ceftriaxone or cefotaxime are preferred). However, ampicillin is ADDED to empirical regimen in children 1–3 months of age to cover Listeria (which is not covered by cephalosporins).

Age Group	Route	Dose	Interval	Max Daily Dose	Duration	Notes
1–3 months (empirical — Listeria cover)	IV	75–100 mg/kg/dose	Every 6 hours (q6h)	300–400 mg/kg/day (max absolute: 12 g/day)	21 days if Listeria confirmed; discontinue if Listeria excluded on culture	Added to ceftriaxone/cefotaxime. Not as monotherapy.
>3 months – 12 years	Ampicillin is generally NOT needed in the empirical regimen (Listeria rare above 3 months in immunocompetent children). Use ceftriaxone + vancomycin ± dexamethasone as standard.	—	—	—	—	Add ampicillin only if immunocompromised or specific Listeria risk identified.
Confirmed Listeria meningitis (any paediatric age)	IV	75–100 mg/kg/dose	Every 6 hours (q6h)	300–400 mg/kg/day (max absolute: 12 g/day)	21 days minimum	First-line definitive therapy. Add gentamicin for synergy (first 7–14 days).

Indian guideline source: IAP Infectious Disease Chapter guidelines; NNF guidelines (for neonatal-infant transition ages); API Textbook.

6. Paediatric Infective Endocarditis — Enterococcus faecalis

⚠️ Specialist only — Paediatric Cardiology and Infectious Disease supervision mandatory.

Age Group	Route	Dose	Interval	Max Daily Dose	Duration	Notes
All paediatric ages	IV	50 mg/kg/dose	Every 4–6 hours (q4–6h)	300 mg/kg/day (max absolute: 12 g/day)	4–6 weeks (6 weeks for prosthetic valve)	Combined with gentamicin (3 mg/kg/day in 3 divided doses) OR ceftriaxone (100 mg/kg/day in 2 divided doses). Same regimen principles as adults.

ℹ️ RHD context in India: Rheumatic heart disease is the most common predisposing condition for IE in Indian children. Enterococcal IE is less common in paediatrics than in adults, but ampicillin remains first-line when identified.

7. IE Prophylaxis — Paediatric (Pre-procedural)

Age Group	Route	Dose	Timing	Max Dose	Notes
All paediatric ages	IV or IM	50 mg/kg as a single dose	30–60 minutes before procedure (preferred: 30 min)	Max 2 g (adult ceiling)	Only when the child cannot take oral amoxicillin (50 mg/kg oral, max 2 g, is preferred). Same high-risk cardiac conditions as in adults.

8. GBS Prophylaxis — Intrapartum (Neonatal Implications)

ℹ️ This is a maternal indication, but prescribers must note the neonatal implications:

If the mother received adequate intrapartum GBS prophylaxis (≥1 dose of ampicillin/penicillin G ≥4 hours before delivery), the neonate can be observed clinically without routine empirical antibiotics (if well-appearing, term, and no other risk factors).
If the mother received inadequate prophylaxis (<4 hours before delivery or no doses given), the neonate should be observed for ≥36–48 hours, and empirical antibiotics (ampicillin + gentamicin) should be started if any signs of sepsis develop.
Indian guideline source: NNF guidelines on EONS risk assessment; IAP guidelines.

Secondary Indications — Paediatric (Off-label, if any)

1. Empirical Febrile Neutropenia — Low-Risk (Combination Regimen)

OFF-LABEL

Context: In resource-limited Indian settings where piperacillin-tazobactam or meropenem may not be available, ampicillin (or ampicillin-sulbactam) combined with gentamicin has been used as an initial empirical regimen for low-risk febrile neutropenia in children. This is NOT standard first-line therapy in well-resourced settings.

Age Group	Route	Dose	Interval	Max Daily Dose	Duration	Notes
>1 month – 12 years	IV	50 mg/kg/dose	Every 6 hours (q6h)	200 mg/kg/day (max absolute: 8 g/day)	Until resolution of neutropenia and 48 hours afebrile	Combined with gentamicin. Step up to ceftazidime/piperacillin-tazobactam/meropenem if no response in 48–72 hours. Specialist only.

Evidence quality: Weak (older paediatric oncology protocols, expert consensus in resource-limited settings)
Indian source: Select paediatric oncology unit protocols in government hospitals
Clearly marked: OFF-LABEL
⚠️ Specialist only — Paediatric Oncology / Haematology supervision mandatory

2. Acute Epiglottitis — Empirical (As part of combination regimen)

OFF-LABEL

Age Group	Route	Dose	Interval	Max Daily Dose	Duration	Notes
All paediatric ages	IV	50 mg/kg/dose	Every 6 hours (q6h)	200 mg/kg/day (max absolute: 8 g/day)	7–10 days	Third-generation cephalosporin (ceftriaxone) is preferred over ampicillin due to beta-lactamase-producing H. influenzae. Ampicillin acceptable only if susceptibility confirmed or if cephalosporins unavailable.

Evidence quality: Weak (clinical practice; epiglottitis itself is rare in India post-Hib vaccination)
Clearly marked: OFF-LABEL
ℹ️ With widespread Hib vaccination in India (Universal Immunisation Programme since 2015), acute epiglottitis has become rare. If suspected, secure the airway FIRST — antibiotic choice is secondary to airway management.

3. Peritoneal Dialysis-Associated Peritonitis — Empirical (Intraperitoneal Ampicillin)

OFF-LABEL

ℹ️ Intraperitoneal (IP) ampicillin is used in some Indian paediatric nephrology units as part of empirical peritonitis treatment in children on PD. Standard first-line is IP vancomycin + IP ceftazidime/gentamicin (ISPD guidelines). Ampicillin may be used for susceptibility-confirmed Enterococcal PD peritonitis.

Dose: 125 mg per litre of dialysis fluid (continuous dosing) OR 500 mg per litre of dialysis fluid once daily (intermittent dosing) — specialist guidance required.
Evidence quality: Weak (extrapolated from adult ISPD guidelines and limited paediatric case series)
Clearly marked: OFF-LABEL
⚠️ Specialist only — Paediatric Nephrology supervision mandatory
No established paediatric dosing. Use only under specialist supervision.

MISSED DOSE / DELAYED DOSE GUIDANCE

Dosing Frequency Context: Ampicillin is most commonly dosed every 6 hours (q6h) — i.e., four times daily. For some indications (meningitis, endocarditis), dosing is every 4 hours (q4h) — i.e., six times daily.

For q6h (four-times-daily) dosing:

ℹ️ If a dose is missed by ≤3 hours: Take/give the missed dose as soon as remembered, then continue the remaining doses at the regular q6h intervals.
ℹ️ If a dose is missed by >3 hours but ≤5 hours: Take/give the missed dose immediately, then take the next scheduled dose at the regular time (even if the interval between doses is shorter than usual — acceptable for ampicillin given its wide therapeutic window).
ℹ️ If a dose is missed by >5 hours: Skip the missed dose entirely. Take the next dose at the regular scheduled time.
⛔ Never double the dose to make up for a missed dose.

For q4h (six-times-daily) dosing (meningitis, endocarditis — hospitalised patients):

⚠️ This dosing frequency is relevant in hospital/NICU/ICU settings where doses are nurse-administered.
If a dose is missed by ≤2 hours: Administer immediately and continue q4h schedule.
If a dose is missed by >2 hours: Administer immediately and reset the q4h clock from the given dose.
⚠️ In meningitis and endocarditis, maintaining time above MIC is critical. Missed doses can lead to treatment failure. Nursing staff should set alarms for round-the-clock q4h administration. If doses are frequently delayed, consider continuous IV infusion (off-label but pharmacologically rational).

For oral dosing (outpatient):

ℹ️ If the patient remembers a missed dose but it is almost time for the next dose (within 2 hours of next scheduled dose), skip the missed dose and take the next dose at the regular time.
ℹ️ Remind patients: ampicillin must be taken on an empty stomach (1 hour before meals or 2 hours after meals) — even when catching up on a missed dose.

PRN dosing: Not applicable — ampicillin is not used PRN.

Prolonged non-adherence / drug holiday guidance:

Ampicillin does not have rebound effects or withdrawal syndrome upon stopping.
⚠️ However, incomplete antibiotic courses carry significant risks:
- Treatment failure and relapse of the infection
- Selection of resistant organisms — a major concern in the Indian AMR context
- For serious infections (meningitis, endocarditis, sepsis): even 1–2 missed doses may allow bacterial regrowth to exceed the killing threshold
ℹ️ If more than 2–3 consecutive doses are missed during a course for a serious infection, contact the treating physician to assess whether:
- The course needs to be extended
- Blood/CSF cultures need to be repeated
- Treatment needs to be changed
No re-titration needed — ampicillin can be safely resumed at the full dose after missed doses. There is no dose-escalation or re-introduction protocol required.
No immunogenicity concern — not a biologic.

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

Reconstitution — Ampicillin Sodium Powder for Injection

Step 1: Reconstitution (to form a concentrated solution)

Vial Size	Diluent to Add	Final Volume (approx.)	Final Concentration (approx.)	Route After This Step
250 mg	1.2 mL Sterile Water for Injection (SWFI)	~1.5 mL	~167 mg/mL	Ready for IM injection or further dilution for IV
500 mg	1.8 mL SWFI	~2.2 mL	~227 mg/mL	Ready for IM injection or further dilution for IV
1 g	3.5 mL SWFI	~4.0 mL	~250 mg/mL	Ready for IM injection or further dilution for IV

ℹ️ Reconstitution diluent: Use Sterile Water for Injection (SWFI) for initial reconstitution. Normal Saline (NS) can also be used. Do NOT use Ringer Lactate for reconstitution.

⚠️ Incompatible diluents: Do NOT reconstitute with dextrose-containing solutions for the initial reconstitution step — ampicillin is less stable in dextrose. Dextrose may be used for further dilution ONLY if the infusion is administered within 1–2 hours (see below).

Step 2: Further Dilution for IV Administration

A. IV Bolus (Slow IV Push):

Dose	Dilute Reconstituted Solution In	Final Volume	Administration Rate
250 mg – 500 mg	Dilute in 5–10 mL SWFI or NS	5–10 mL	Administer slowly over 3–5 minutes
1 g – 2 g	Dilute in 10–20 mL SWFI or NS	10–20 mL	Administer slowly over 3–5 minutes (10–15 minutes preferred for 2 g dose)

⚠️ Do NOT give by rapid IV push. Rapid injection may cause seizures (especially in neonates and patients with renal impairment) and local pain/phlebitis.

B. IV Intermittent Infusion:

Dose	Compatible IV Fluid	Dilution Volume	Final Concentration	Infusion Rate
500 mg – 2 g	Normal Saline (0.9% NaCl) — PREFERRED	50–100 mL	10–20 mg/mL	Infuse over 15–30 minutes
500 mg – 2 g	5% Dextrose (D5W) — acceptable but less stable	50–100 mL	10–20 mg/mL	⚠️ Must infuse within 1 hour of preparation in D5W. NS strongly preferred.

ℹ️ Why NS is preferred: Ampicillin undergoes accelerated degradation in dextrose solutions. Solutions in D5W lose significant potency (>10%) within 2–4 hours at room temperature. In NS, stability is maintained for 8 hours at room temperature.

For paediatric/neonatal doses — worked calculation example:

💡 Weight-based IV dosing example (neonatal sepsis):

Patient: 3 kg term neonate, Day 2 of life. Dose: 50 mg/kg = 150 mg IV q8h.

Preparation:

1. Reconstitute a 250 mg vial with 1.2 mL SWFI → final concentration ~167 mg/mL, final volume ~1.5 mL.
2. Withdraw 0.9 mL (= 150 mg) from the reconstituted vial.
3. For IV bolus: Dilute 0.9 mL in 4–5 mL NS → give slowly over 3–5 minutes.
4. For IV infusion: Dilute 0.9 mL in 10–15 mL NS → infuse over 15–30 minutes using a syringe pump.

Discard the remaining reconstituted solution if no preservative and within the timeframe (see Stability below).

💡 Neonatal meningitis example:

Patient: 2.5 kg term neonate. Dose: 100 mg/kg = 250 mg IV q8h.

Reconstitute a 250 mg vial with 1.2 mL SWFI. Withdraw entire volume (~1.5 mL = 250 mg). Dilute in 5–10 mL NS. Infuse over 15–30 minutes via syringe pump.

Stability After Reconstitution

Storage Condition	Stability (in NS)	Stability (in D5W)	Stability (reconstituted, undiluted in SWFI)
Room temperature (25°C)	8 hours	1–2 hours (use immediately)	1 hour
Refrigeration (2–8°C)	24 hours	2–4 hours	8 hours
Protected from light?	Not light-sensitive (no special protection needed)	—	—

⚠️ Indian context — hot climate: In Indian hospital wards and PHCs without air conditioning, ambient temperature may exceed 30–35°C during summer. Reconstituted ampicillin degrades faster at higher temperatures. Prepare fresh immediately before administration. Do not prepare in advance and leave at ambient temperature. If using in a non-AC setting, administer within 30 minutes of reconstitution.

Multi-Dose Vial Handling

ℹ️ Ampicillin powder for injection vials are generally single-dose vials without preservative. Once reconstituted, the vial should be used for a single patient and any remaining solution discarded.

⛔ Do NOT use a single reconstituted vial for multiple patients — contamination risk. This is especially critical for neonatal use.

For neonatal and intrathecal use: Use preservative-free single-dose vials only.

Y-site / Line Compatibility

Compatible (generally — verify institutional guidelines):

Normal Saline
Heparin (in NS)
Potassium chloride (in NS)
Acyclovir
Magnesium sulphate
Calcium gluconate (check concentration)

Known Incompatibilities — Do NOT mix with or infuse through the same line simultaneously:

Incompatible Drug/Solution	Reason
⛔ Aminoglycosides (gentamicin, amikacin, tobramycin)	Physical and chemical incompatibility — ampicillin inactivates aminoglycosides if mixed in the same IV line or bag. Must be given through separate IV lines or at least flushed between drugs (≥10 mL NS flush). If only one IV line available: give ampicillin first, flush with 10–20 mL NS, then give gentamicin.
⛔ Sodium bicarbonate	Accelerates hydrolysis of ampicillin
⛔ Dextrose solutions (for Y-site mixing)	Reduced stability
⛔ Metronidazole IV	Physical incompatibility
⛔ Midazolam	Physical incompatibility
⛔ Lipid emulsions / parenteral nutrition (TPN)	Physical incompatibility

⚠️ Critical nursing note for neonatal ampicillin + gentamicin: The most common empirical neonatal sepsis regimen involves BOTH ampicillin and gentamicin. These are chemically incompatible if mixed. NEVER add both drugs to the same IV bag or syringe. Always administer separately with a NS flush between them.

Special Administration Notes

Oral administration:

✔ Capsules: Swallow whole with a full glass of water. Do NOT crush or open capsules.
✔ Oral suspension: Shake well before each dose. Use a calibrated oral syringe or measuring cup (NOT a household teaspoon/tablespoon — dosing errors common in Indian practice).
⚠️ Take on an empty stomach — 1 hour before meals or 2 hours after meals. Food significantly reduces absorption.
✔ Oral suspension can be administered via nasogastric (NG) or orogastric (OG) tube. Flush tube with 5–10 mL water before and after administration.

IM injection:

Adults: Inject deep IM into a large muscle mass (gluteal or deltoid). Maximum volume per IM site: 2 mL in deltoid, 5 mL in gluteal.
Children: Inject into the anterolateral thigh (preferred in infants and young children) or deltoid (older children). Maximum volume per IM site: 0.5 mL (neonates), 1 mL (infants), 2 mL (older children).
ℹ️ IM injection of ampicillin is painful. Adding 1% lidocaine (without adrenaline) to the reconstitution diluent reduces injection pain — however, this practice should only be done if explicitly allowed by institutional protocol and NOT for IV administration.

Extravasation:

ℹ️ Low-risk for tissue injury. Ampicillin is not a vesicant. If extravasation occurs, stop infusion, apply warm compress, and monitor. Significant tissue necrosis is rare but can occur with concentrated solutions.

Filter requirements: No in-line filter required for standard IV infusion.

Cold-Chain Drug Guidance

ℹ️ Ampicillin powder for injection does NOT require cold chain storage. Store at room temperature (below 25°C preferred, acceptable up to 30°C). Protect from moisture.

Before reconstitution: Room temperature. Keep in original packaging. Protect from moisture and excessive heat.
After reconstitution: Use promptly. If not used immediately, refrigerate and use within timeframes specified in Stability section above. Do NOT freeze reconstituted solutions.

Oral formulations:

Capsules: Store at room temperature below 25°C. Protect from moisture.
Dry syrup powder (before reconstitution): Store at room temperature below 25°C. Protect from moisture.
Reconstituted oral suspension: ⚠️ Store in refrigerator (2–8°C). Discard after 7–14 days (check manufacturer’s instructions on the bottle — varies by brand). If refrigerator is unavailable, store in the coolest available location and use within 7 days. Do NOT freeze.

💡 Practical Indian context note: In rural and semi-urban settings without reliable refrigeration, reconstituted oral suspension may degrade faster. Counsel caregivers to store the bottle in the coolest part of the house (away from kitchen, stove, and direct sunlight). If ambient temperature consistently exceeds 30°C and refrigeration is unavailable, consider prescribing capsules (for older children who can swallow them) or parenteral therapy. If oral suspension is the only option, prepare smaller volumes and reconstitute fresh every few days if feasible.

RENAL ADJUSTMENT

eGFR formula specification: Dosing adjustments below are based on Cockcroft-Gault calculated CrCl (as original pharmacokinetic studies used this method). CKD-EPI eGFR values may slightly differ, particularly in elderly and low-muscle-mass patients — clinical judgement advised. For practical purposes, either eGFR (CKD-EPI) or CrCl (Cockcroft-Gault) may be used, but be aware that in elderly, cachectic, or amputee patients, CKD-EPI may overestimate actual renal function relative to Cockcroft-Gault.

Rationale: Ampicillin is 60–80% renally excreted (unchanged drug via glomerular filtration and active tubular secretion). Half-life increases from ~1–1.8 hours (normal renal function) to 7–20 hours in severe renal impairment/ESRD. Dose adjustment is by interval extension (not dose reduction) — this preserves the peak concentration needed for time-dependent killing while preventing drug accumulation.

Standard Renal Dosing Adjustment Table:

eGFR / CrCl (mL/min)	Dose Adjustment	Dosing Interval	Notes
>50	No adjustment needed	Standard intervals: q6h (standard) or q4h (meningitis/endocarditis)	Full dose, full frequency
30–50	No dose reduction per dose	Extend interval to every 6–8 hours (if baseline q6h) or every 6 hours (if baseline q4h)	Monitor clinical response. Standard doses still achieve adequate peak levels.
15–30	No dose reduction per dose	Extend interval to every 8–12 hours	⚠️ Monitor for signs of drug accumulation (neurotoxicity — myoclonus, seizures). Serum levels may guide therapy in critical infections (meningitis, endocarditis) if TDM available.
<15 (non-dialysis)	No dose reduction per dose	Extend interval to every 12–24 hours	⚠️ High risk of accumulation. Monitor closely for neurotoxicity. In serious infections (meningitis, endocarditis), balance the risk of underdosing vs accumulation — infectious disease specialist input recommended.
Haemodialysis (HD)	Standard dose	Every 12–24 hours + supplemental dose after each dialysis session	Ampicillin is significantly dialysable (20–50% removed per standard 4-hour HD session). Give a supplemental dose of 250 mg–1 g IV (same as the individual dose) after each HD session. Time the regular dose to be given post-dialysis when possible.
Peritoneal dialysis (PD)	Standard dose per dose	Every 12–24 hours	Moderately removed by PD. For PD-related peritonitis: can give intraperitoneal ampicillin (125 mg/L continuous or 500 mg/L intermittent — specialist guidance, see Paediatric secondary indications for PD peritonitis).
CRRT (CVVH / CVVHD / CVVHDF)	Standard dose per dose (may need dose INCREASE)	Every 6–8 hours (closer to standard dosing intervals than for intermittent HD)	⚠️ CRRT removes ampicillin continuously. Standard intervals (or near-standard) are usually needed. Dose depends on CRRT modality, flow rates, and filter type. Recommended starting: 1–2 g IV q6–8h for serious infections. Adjust based on clinical response. ICU pharmacist input recommended.

Augmented Renal Clearance (ARC):

⚠️ Important for ICU patients: Young, non-elderly ICU patients (especially those with sepsis, trauma, burns, febrile neutropenia) commonly develop ARC (CrCl >130 mL/min). Ampicillin is primarily renally cleared → ARC causes subtherapeutic drug levels with standard dosing.

Recommendations for ARC:

Consider increasing dose frequency to every 4 hours (q4h) even for non-meningeal indications
Consider higher individual doses: 2 g q4h for serious infections
Prolonged or continuous IV infusion (off-label but pharmacologically rational) may be considered in select ICU patients to maximise time above MIC
If available, therapeutic drug monitoring (TDM) can guide dosing — target fT > MIC ≥ 60–70% of the dosing interval
Indian context: ARC is under-recognised in many Indian ICUs. A measured 8-hour or 24-hour CrCl (from timed urine collection) is more accurate than calculated eGFR for detecting ARC. Consider this in young sepsis patients who are not responding despite “adequate” doses.

Indian guideline source for renal adjustment: AIIMS Nephrology protocols (supportive); dose adjustments are standard across international and Indian pharmacokinetic references. National Formulary of India — Ampicillin monograph.

HEPATIC ADJUSTMENT

Ampicillin undergoes minimal hepatic metabolism (~10–15% metabolised; no involvement of CYP enzymes). Primary elimination is renal.

Hepatic Impairment Severity	Dose Adjustment
Mild (Child-Pugh A)	No adjustment required
Moderate (Child-Pugh B)	No adjustment required
Severe (Child-Pugh C)	No adjustment required for the drug itself

ℹ️ Clinical note for severe liver disease:

While ampicillin itself does not require hepatic dose adjustment, patients with severe cirrhosis (Child-Pugh C) frequently have concomitant renal impairment (hepatorenal syndrome, impaired GFR) — always check and adjust for renal function.
Patients with cirrhosis and ascites have an expanded Vd → initial loading doses for serious infections (e.g., SBP) should NOT be reduced.
Hypoalbuminaemia in cirrhosis: Minimal clinical impact on ampicillin (only 15–28% protein bound — low protein binding means free drug fraction is not dramatically altered by hypoalbuminaemia).
Active metabolites: Penicilloic acid (inactive) — does not accumulate clinically in liver disease.

Concurrent hepatotoxin note:
ℹ️ Ampicillin itself has a very low risk of hepatotoxicity (rare idiosyncratic cholestatic hepatitis — much less common than with amoxicillin-clavulanate). However, when combined with known hepatotoxic drugs commonly used in Indian practice (particularly relevant combinations):

Isoniazid + Rifampicin (anti-TB therapy): No specific pharmacokinetic interaction, but monitor LFTs as the anti-TB drugs are hepatotoxic. Ampicillin is occasionally co-prescribed with anti-TB drugs when concurrent bacterial infection requires treatment.
Methotrexate: Penicillins (including ampicillin) can reduce renal clearance of methotrexate → increased risk of methotrexate toxicity (see Major Drug Interactions). Monitor LFT and methotrexate levels if co-administered.
Valproate / Anti-retrovirals: No specific hepatotoxic interaction with ampicillin expected.

No formal hepatic dosing data exists, but no adjustment is needed based on pharmacokinetic principles (minimal hepatic metabolism, low protein binding, no active metabolite accumulation).

CONTRAINDICATIONS

⛔ Absolute Contraindications — Ampicillin must NEVER be used in these situations:

Contraindication	Clinical Rationale
⛔ Known anaphylaxis or severe immediate (Type I) hypersensitivity to ampicillin, any penicillin, or any component of the formulation	Risk of fatal anaphylaxis. Even a single dose can trigger life-threatening anaphylaxis in truly penicillin-allergic patients with documented Type I (IgE-mediated) reactions.
⛔ Known anaphylaxis to any beta-lactam antibiotic (with confirmed cross-reactivity or where cross-reactivity cannot be excluded and desensitisation is not available)	Cross-reactivity risk (see below).
⛔ Concurrent use with oral live typhoid vaccine (Ty21a / Vivotif)	Ampicillin (and other antibiotics active against Salmonella) can inactivate the live vaccine strain, rendering the vaccine ineffective. Separate administration by at least 3 days (finish antibiotic course ≥3 days before administering live typhoid vaccine, or delay vaccine until after antibiotic course). Inactivated Vi polysaccharide typhoid vaccine is not affected.

Allergy Cross-Reactivity:

Related Drug/Class	Cross-Reactivity with Ampicillin	Notes
Other penicillins (amoxicillin, piperacillin, cloxacillin, penicillin G/V, etc.)	High (~100% for IgE-mediated allergy to the penicillin core)	All penicillins share the 6-APA (6-aminopenicillanic acid) core. A patient with confirmed anaphylaxis to ANY penicillin should be considered allergic to ALL penicillins, including ampicillin.
Amoxicillin	Very high (~100%)	Amoxicillin and ampicillin are structural analogues (aminopenicillins) — differ only by a hydroxyl group. Cross-reactivity is virtually complete. A patient allergic to amoxicillin is almost certainly allergic to ampicillin and vice versa.
Cephalosporins	Low but clinically significant: ~1–2% overall; higher (~10–15%) for first-generation cephalosporins and cephalosporins with similar R1 side chains	Cross-reactivity is side-chain dependent, NOT core-ring dependent (older data suggesting 10% cross-reactivity based on common contaminants has been revised downward). Cephalosporins with similar R1 side chains to ampicillin (e.g., cephalexin, cefadroxil, cefaclor) carry higher cross-reactivity risk. Third-generation cephalosporins (ceftriaxone, cefotaxime) have very low cross-reactivity (~0.5–1%).
Carbapenems (meropenem, imipenem, ertapenem)	Very low (~0.5–1%)	Can generally be used safely in penicillin-allergic patients (except in documented carbapenem allergy). Use with caution and monitoring for the first dose if history of severe penicillin allergy.
Monobactams (aztreonam)	Negligible (<0.1%)	No significant cross-reactivity with penicillins. Can be used safely in penicillin-allergic patients.

ℹ️ Indian context on penicillin allergy: Many patients in India report “penicillin allergy” based on non-specific symptoms (GI upset, non-urticarial rash). True IgE-mediated penicillin allergy is present in <10% of patients who report it. Penicillin skin testing is the gold standard for confirming/excluding IgE-mediated allergy but is not widely available in India. If the reported reaction was a non-severe, non-immediate maculopapular rash (common with ampicillin — see Adverse Effects), this is usually NOT an IgE-mediated allergy and does NOT contraindicate future aminopenicillin use — though clinical judgement is needed. Document the nature of the previous reaction carefully.

💡 Ampicillin-specific rash vs true allergy:
A maculopapular (non-urticarial), non-pruritic rash occurring 5–14 days after starting ampicillin is very common (~5–10% of recipients, up to 70–100% in patients with EBV/CMV mononucleosis or concurrent allopurinol). This is a non-allergic, non-IgE-mediated reaction and does NOT predict future anaphylaxis. It should be documented as “ampicillin rash (non-allergic)” — NOT as “penicillin allergy” — to prevent inappropriate penicillin avoidance in future.

CAUTIONS

⚠️ High-Priority Cautions

Condition	Risk	Required Monitoring / Action
⚠️ Renal impairment (eGFR <30 mL/min)	Accumulation → increased risk of neurotoxicity (myoclonus, seizures, encephalopathy)	Extend dosing interval per Renal Adjustment table. Monitor for neurological symptoms. Consider serum level monitoring if available. Check serum creatinine at baseline and periodically.
⚠️ History of non-anaphylactic penicillin allergy (e.g., delayed maculopapular rash)	Near-absolute contraindication if the previous reaction was severe/uncertain; relative caution if the previous reaction was clearly non-IgE-mediated (delayed, maculopapular, non-urticarial)	Careful history: Nature of previous reaction (timing, morphology, severity). If uncertain: penicillin skin testing (if available), or use an alternative antibiotic. If previous reaction was clearly a non-allergic ampicillin rash (see above): may cautiously re-challenge under observation. If previous reaction involved angioedema, bronchospasm, hypotension, or urticaria within 1 hour: treat as ⛔ contraindication.
⚠️ Infectious mononucleosis (EBV/CMV) — confirmed or suspected	Extremely high incidence (70–100%) of generalised maculopapular rash if ampicillin/amoxicillin is given during acute EBV mononucleosis	Avoid ampicillin in patients with suspected or confirmed infectious mononucleosis (glandular fever). This rash is NOT a true allergy but is distressing, extensive, and may be misdiagnosed as allergy, leading to lifelong inappropriate penicillin avoidance. If a pharyngitis patient may have EBV (teenage/young adult, lymphadenopathy, hepatosplenomegaly, atypical lymphocytes), do NOT treat with ampicillin/amoxicillin — use penicillin V or a macrolide if bacterial pharyngitis is also suspected.
⚠️ Seizure disorder / epilepsy	High-dose IV ampicillin (particularly in renal impairment) can lower seizure threshold and cause myoclonus/seizures	Use renal-adjusted dosing. Monitor closely. Seizure risk is dose-dependent and more common with doses >150 mg/kg/day in the setting of renal impairment.
⚠️ Concurrent allopurinol use	Markedly increased incidence of maculopapular skin rash (ampicillin rash) — up to 15–20% vs 5–10% without allopurinol	Warn the patient about rash. If rash develops, differentiate from true allergic urticaria. Consider using an alternative antibiotic if the patient is on allopurinol and has another option. The rash is non-allergic but may lead to unnecessary future penicillin avoidance.
⚠️ Concurrent methotrexate use	Reduced renal clearance of methotrexate → risk of methotrexate toxicity (pancytopaenia, mucositis, nephrotoxicity)	See Major Drug Interactions. Monitor methotrexate levels and CBC/renal function closely. Consider using a non-penicillin antibiotic.
⚠️ Prolonged antibiotic use (>7–10 days)	Risk of superinfection: Clostridioides difficile-associated diarrhoea (CDAD), oral/vaginal candidiasis	Monitor for diarrhoea (especially watery/bloody diarrhoea). Test for C. difficile toxin if suspected. Treat candidiasis symptomatically.

Standard Cautions

Condition	Notes
Asthma / atopy	Slightly higher risk of hypersensitivity reactions (though most penicillin allergies are not IgE-mediated). Obtain allergy history carefully.
Diabetes mellitus	Oral suspension contains sucrose — may affect blood glucose marginally. Negligible clinical impact at standard doses.
Patients on oral contraceptives (COCs)	Historical concern that antibiotics reduce COC efficacy. Current evidence does NOT support this for ampicillin (except possibly in cases of severe diarrhoea reducing enterohepatic recycling of ethinylestradiol). However, standard UK/Indian practice is to advise additional barrier contraception during and for 7 days after a short antibiotic course (precautionary — see Moderate Drug Interactions).
Patients on warfarin or acenocoumarol	Ampicillin may modestly alter INR (both increases and decreases reported). Monitor INR more frequently during and shortly after ampicillin course.
History of GI disease, particularly colitis	Increased susceptibility to antibiotic-associated diarrhoea and C. difficile colitis.
Sodium restriction (parenteral use)	Each 1 g of ampicillin sodium contains ~66.7 mg (2.9 mEq) of sodium. Relevant in patients on sodium-restricted diets (heart failure, cirrhosis with ascites) or in neonates receiving high-dose IV ampicillin. Calculate cumulative sodium load.

PREGNANCY

Parameter	Detail
Overall safety statement	✔ Compatible with use in pregnancy. Ampicillin is one of the safest antibiotics in pregnancy and has been used extensively in all trimesters for decades with a well-established safety profile. No evidence of teratogenicity in human or animal studies at therapeutic doses.
Former US-FDA Pregnancy Category	Category B (no evidence of risk in humans, based on adequate studies — provided for reference only; India does not use this classification system)
Teratogenicity window	No teratogenic risk identified at any stage of pregnancy. Safe throughout all trimesters including the first trimester organogenesis period (weeks 3–8 post-conception).
Trimester-specific notes	First trimester: Safe. No association with congenital malformations. Second trimester: Safe. Used for UTI treatment, GBS screening/treatment. Third trimester: Safe. Specifically recommended for intrapartum GBS prophylaxis (see Indications). Used in PPROM latency regimen. Used in chorioamnionitis treatment.
Preferred alternatives in Indian obstetric practice	Ampicillin IS itself one of the preferred antibiotics in pregnancy. Other safe alternatives in pregnancy: amoxicillin (oral — better bioavailability), cephalexin, cefuroxime, erythromycin, azithromycin (for atypicals), nitrofurantoin (UTI — avoid at term).
When it may be used	First-line choice for many infections in pregnancy — no restriction required. Specifically indicated for: intrapartum GBS prophylaxis, PPROM latency antibiotics, chorioamnionitis treatment, susceptible UTI, Listeria infections.
What to monitor	Routine monitoring as for any antibiotic. No specific fetal monitoring required due to ampicillin itself. Monitor for allergic reactions (standard). If used for GBS prophylaxis: ensure adequate timing (≥4 hours before delivery).
Pre-conception counselling	Not required — no need for pre-conception washout or supplementation specific to ampicillin. Standard antenatal folate supplementation applies regardless of ampicillin use.
Contraception requirement	Not required — ampicillin is not teratogenic and does not require pregnancy prevention measures.

Pregnancy-specific PK note: ⚠️ GFR increases by 40–65% during pregnancy → increased renal clearance of ampicillin → serum levels may be lower than in non-pregnant adults at the same dose. For serious infections (GBS prophylaxis, chorioamnionitis, listeriosis, pyelonephritis), use full therapeutic doses without reduction. Some experts advocate slightly higher doses or shorter intervals in late pregnancy, but standard doses remain the norm in Indian practice.

Pregnancy Prevention Programme / Registry:
Not applicable — ampicillin does not require a pregnancy prevention programme. No pregnancy exposure registry exists or is needed for ampicillin.

Fertility Effects:
No known effect on male or female fertility. No impact on spermatogenesis, ovulation, or ovarian reserve at therapeutic doses. No washout period before planned conception needed.

LACTATION

Parameter	Detail
Compatible with breastfeeding?	✔ Yes — compatible with breastfeeding. Ampicillin is one of the safest antibiotics during lactation.
Drug levels in milk	Low. Ampicillin is excreted in breast milk in small amounts. Relative Infant Dose (RID): <1–2% of the maternal weight-adjusted dose — well below the 10% threshold of concern.
Preferred alternatives	Ampicillin IS itself a preferred antibiotic during lactation. Alternatives (if needed for coverage reasons): amoxicillin, cephalexin, erythromycin.
What to monitor in the breastfed infant	Monitor for: loose stools/diarrhoea (most common — due to alteration of infant gut flora), oral candidiasis (thrush), feeding difficulties, skin rash (rare — possible sensitisation). In most cases, no adverse effects are observed in the infant.
Timing advice	Not critical — the amount excreted is very low regardless of timing. If the mother wishes to minimise infant exposure, she may take the dose immediately after a breastfeed and feed from the other breast for the next feed — but this is a precaution, not a medical necessity.

Effect on milk production:
No known effect on milk production (neither suppresses nor enhances lactation).

Temporary incompatibility guidance:
Not applicable — ampicillin is fully compatible with breastfeeding. No need to withhold breastfeeding, pump and discard, or delay feeds.

ELDERLY

Definition: ≥60 years (consistent with Indian Census and National Programme for Health Care of the Elderly).

Parameter	Detail
Recommended starting dose	Standard adult dose UNLESS renal function is impaired. Do NOT reflexively reduce dose based on age alone — adjust based on eGFR/CrCl. For serious infections (meningitis, endocarditis, sepsis): full therapeutic doses are essential even in the elderly.
Titration	Not applicable — ampicillin is not titrated. Dose is set by indication and renal function.
Slower titration needed?	Not applicable.
Extra risks specific to elderly	1. Renal function decline: Age-related GFR decline means most elderly patients have some degree of renal impairment — always calculate eGFR/CrCl before prescribing and adjust interval accordingly. Serum creatinine alone is misleading in elderly (low muscle mass → “normal” creatinine despite reduced GFR). 2. Clostridioides difficile colitis: Elderly patients are at significantly higher risk of antibiotic-associated C. difficile infection — avoid unnecessary prolongation of ampicillin courses. Monitor for diarrhoea. 3. Neurotoxicity: High-dose IV ampicillin in elderly with impaired renal function → risk of myoclonus, seizures, encephalopathy. Ensure renal dose adjustment. 4. Fluid and sodium load (IV): Elderly patients with heart failure or fluid overload — monitor cumulative sodium and fluid load from IV ampicillin infusions. 5. Polypharmacy interactions: Elderly patients are frequently on warfarin/acenocoumarol (ampicillin may alter INR), allopurinol (increased rash risk), methotrexate (reduced clearance). Review medication list.
Beers Criteria / STOPP-START	Ampicillin itself is NOT listed in the Beers Criteria or STOPP-START criteria as a potentially inappropriate medication in the elderly. However, the general principle of antibiotic stewardship (avoid unnecessary courses, shortest effective duration) applies.
Monitoring frequency adjustments	Check renal function (serum creatinine + eGFR calculation) before starting and at least once during a course lasting >5 days. Monitor for diarrhoea (C. difficile risk).
Common clinical scenarios in elderly Indian patients	Elderly with Enterococcal UTI: Common in elderly males with prostatic obstruction and indwelling catheters. Ampicillin is first-line for susceptibility-confirmed E. faecalis UTI. Elderly with Listeria meningitis: Age >50 years is a specific risk factor — always include ampicillin in empirical meningitis regimens in this age group. Elderly post-operative patients with intra-abdominal infections: Triple regimen (ampicillin + gentamicin + metronidazole) — monitor renal function closely as both ampicillin and gentamicin require renal adjustment.

Anticholinergic burden:
No anticholinergic burden. Ampicillin has no anticholinergic properties. ACB score: 0. No risk of cumulative anticholinergic burden when combined with other medications.

Deprescribing guidance:
Deprescribing: Not applicable. Ampicillin is used as a short-course (acute therapy) antibiotic, not a chronic maintenance medication. It is not a candidate for deprescribing protocols. Ensure the prescribed course duration is appropriate and not unnecessarily prolonged.

MAJOR DRUG INTERACTIONS

An interaction qualifies as MAJOR if: the combination is contraindicated, can cause a life-threatening adverse event, causes ≥2-fold change in AUC/Cmax, requires mandatory dose adjustment, or has documented serious harm.

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
⛔ Methotrexate	Ampicillin (and other penicillins) inhibits the renal tubular secretion of methotrexate via OAT transporter competition. Reduced renal clearance of methotrexate.	⚠️ Risk of severe methotrexate toxicity: pancytopaenia (bone marrow suppression), severe mucositis, nephrotoxicity, hepatotoxicity. Can be fatal.	Gradual onset — toxicity develops over days as methotrexate accumulates.	⛔ Avoid combination if possible. If unavoidable (e.g., concurrent infection in a patient on methotrexate): monitor methotrexate levels closely, monitor CBC and renal function daily, ensure adequate hydration and urinary alkalinisation. Consider leucovorin rescue. Rheumatology/Oncology input recommended. Use a non-penicillin antibiotic if feasible.
⛔ Oral live typhoid vaccine (Ty21a)	Ampicillin kills the live vaccine Salmonella typhi strain → renders vaccine ineffective.	Complete vaccine failure. No immune response. Patient remains unprotected.	Acute onset — immediate inactivation of vaccine organisms.	⛔ Do NOT administer oral live typhoid vaccine during ampicillin therapy or within 3 days of completing the course. Delay vaccine until ≥3 days after last ampicillin dose. Inactivated Vi polysaccharide typhoid vaccine (injectable) is NOT affected and can be given at any time.
⛔ Other live bacterial vaccines (BCG, live oral cholera vaccine)	Same mechanism — antibacterial activity against vaccine organisms.	Reduced vaccine efficacy.	Acute onset.	⛔ Delay live bacterial vaccines until ≥3 days after completing ampicillin course. Live viral vaccines (MMR, varicella, OPV) are NOT affected.
⚠️ Warfarin / Acenocoumarol	Multiple mechanisms: (1) Disruption of gut flora → reduced vitamin K synthesis → enhanced anticoagulant effect; (2) Possible displacement from protein binding (minimal for ampicillin — low protein binding); (3) Direct but poorly characterised effect on coagulation.	⚠️ Increased INR → risk of bleeding. Both increases and decreases in INR have been reported, but increases are more common and clinically significant.	Gradual onset — INR changes typically manifest within 3–7 days of starting ampicillin.	Monitor INR within 3–5 days of starting or stopping ampicillin in patients on warfarin/acenocoumarol. Adjust anticoagulant dose as needed. Educate patient on bleeding signs.
⚠️ Allopurinol	Mechanism unclear — possibly immunological synergy leading to delayed hypersensitivity rash. NOT a pharmacokinetic interaction.	⚠️ Markedly increased incidence of maculopapular skin rash (~15–20% incidence vs ~5–10% without allopurinol). The rash is non-allergic (Type IV, delayed) and NOT a contraindication to future penicillin use — but is distressing and may be wrongly labelled as “penicillin allergy.”	Gradual onset — rash typically appears 5–14 days after starting ampicillin.	Warn patient about high probability of rash. Document rash as “ampicillin/allopurinol-associated rash — NOT IgE-mediated allergy.” Consider using an alternative antibiotic (e.g., cephalosporin, fluoroquinolone) if appropriate for the infection. If ampicillin is essential (e.g., Enterococcal endocarditis), continue treatment — the rash is benign and self-limiting after stopping ampicillin.

Food-Drug Interactions (MAJOR):

Food/Substance	Mechanism	Clinical Effect	Action Required
⚠️ Food (all meals)	Food delays gastric emptying and reduces ampicillin absorption by up to 50%. Unlike amoxicillin (food does not affect absorption), oral ampicillin bioavailability is significantly food-dependent.	Reduced oral ampicillin levels → subtherapeutic concentrations → potential treatment failure.	⚠️ Mandatory: Take oral ampicillin on an empty stomach — 1 hour before meals or 2 hours after meals. This is not optional for ampicillin (unlike amoxicillin which can be taken with food). If the patient consistently takes ampicillin with food, consider switching to amoxicillin (food-independent absorption) if appropriate for the infection.

Herb-Drug / Traditional Medicine Interactions (if MAJOR):

No MAJOR interactions with traditional Indian medicines have been documented for ampicillin specifically. General caution: herbal preparations containing antimicrobial compounds (e.g., neem extracts, Berberine/Daruharidra) — no pharmacokinetic interaction expected, but potential for additive GI upset.

MODERATE DRUG INTERACTIONS

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Probenecid	Inhibits active renal tubular secretion of ampicillin (OAT1/OAT3 inhibition) → reduced renal clearance.	Increased ampicillin serum levels (AUC increased by ~50–100%) and prolonged half-life. May be beneficial in some situations (higher drug levels) but increases risk of dose-dependent adverse effects.	Acute onset — effect begins with first co-administered dose.	Can be used deliberately to increase ampicillin levels (historical use, now uncommon). If inadvertently co-prescribed: be aware of higher ampicillin levels. Consider reducing ampicillin dose frequency (e.g., q8h instead of q6h) if prolonged co-administration. Monitor for neurotoxicity at high doses.
Aminoglycosides (gentamicin, amikacin, tobramycin) — in vitro inactivation	Ampicillin chemically inactivates aminoglycosides when mixed in the same IV solution or infused through the same line. This is an in-vitro (pharmaceutical) incompatibility, NOT an in-vivo pharmacological antagonism. In vivo, the combination is synergistic.	⚠️ If mixed in the same bag/line: aminoglycoside activity is destroyed → aminoglycoside component becomes ineffective. The clinical consequence is therapeutic failure of the aminoglycoside, NOT a toxic interaction.	Acute onset — degradation begins within minutes of mixing.	Do NOT mix ampicillin and aminoglycosides in the same IV bag, syringe, or Y-site. Administer separately with an NS flush between them (≥10 mL). In vivo, the combination is deliberately used for synergy (neonatal sepsis, Enterococcal endocarditis, Listeria infections) — the drugs must simply be administered separately.
Oral contraceptive pills (COCs)	Historical concern: ampicillin disrupts gut flora → reduces enterohepatic recycling of ethinylestradiol → lower ethinylestradiol levels → reduced contraceptive efficacy. Current evidence does NOT strongly support a clinically significant pharmacokinetic interaction for most penicillins. However, GI side effects (diarrhoea, vomiting) can reduce COC absorption.	Theoretical risk of reduced contraceptive efficacy. Actual failure rate attributable to ampicillin is unproven but historically reported.	Gradual onset — would manifest over the cycle.	Precautionary measure (standard Indian and UK practice): Advise additional barrier contraception (condoms) during the antibiotic course and for 7 days after completing ampicillin. If the 7-day period extends beyond the end of the active pill pack, skip the pill-free interval and start the next active pack immediately (for monophasic COCs). This is a precautionary recommendation — the interaction is likely clinically insignificant for most patients.
Chloramphenicol	Bacteriostatic agent (chloramphenicol) may antagonise the bactericidal effect of ampicillin (which requires actively dividing bacteria for cell-wall disruption).	Potential antagonism → reduced killing efficacy of ampicillin, particularly in meningitis where bactericidal activity is essential.	Acute onset.	Avoid concurrent use if possible, especially for meningitis. If chloramphenicol is the only available alternative (resource-limited settings), use sequentially rather than simultaneously. In meningitis, a bactericidal agent (ampicillin, ceftriaxone) is strongly preferred over chloramphenicol.
Tetracyclines (doxycycline, tetracycline)	Bacteriostatic agent — may theoretically antagonise bactericidal effect of ampicillin (same mechanism as chloramphenicol).	Potential antagonism — clinical significance uncertain but theoretical basis is sound.	Acute onset.	Avoid concurrent use when both are intended for the same infection. If used for different indications in the same patient (e.g., ampicillin for UTI + doxycycline for acne), the clinical significance is minimal as different tissue targets are involved.
Mycophenolate mofetil (MMF)	Ampicillin may disrupt gut flora that normally hydrolyse the enterohepatic recycled glucuronide metabolite of mycophenolate → reduced reabsorption → lower mycophenolic acid (MPA) levels.	Reduced MPA levels → risk of transplant rejection (in transplant patients on MMF-based immunosuppression).	Gradual onset — over days.	Monitor MPA trough levels (if TDM available) during and shortly after ampicillin course. Watch for signs of rejection (in transplant patients). Consider alternative antibiotics if feasible. In practice, short courses of ampicillin are unlikely to have a major impact, but prolonged courses warrant monitoring.
Atenolol	Possible reduction in atenolol oral absorption when co-administered with ampicillin (mechanism unclear — possibly altered GI transit). Clinical significance is modest.	Slightly reduced atenolol levels.	Acute onset.	Clinically insignificant in most cases. Separate administration by 1–2 hours if concerned. Monitor blood pressure.

Food-Drug Interactions (MODERATE):

Food/Substance	Mechanism	Clinical Effect	Action Required
Dairy products (milk, curd/dahi, lassi, paneer)	No specific chelation (unlike tetracyclines). However, dairy as part of a meal contributes to the general food effect of reduced absorption.	Reduced ampicillin absorption if taken with meals including dairy.	Take on an empty stomach. Dairy avoidance beyond the general food-effect guidance is not necessary.

Traditional Medicine Interactions (MODERATE):

Substance	Interaction	Action
Triphala (commonly used Ayurvedic preparation)	Mild antimicrobial properties + laxative effect. May contribute to diarrhoea when combined with ampicillin. No pharmacokinetic interaction.	ℹ️ Traditional medicine interaction. No dose adjustment needed. Warn patient about additive diarrhoea risk.
Giloy / Guduchi (Tinospora cordifolia)	Immunomodulatory properties. No documented pharmacokinetic interaction with ampicillin. Theoretical concern that immunostimulation could alter infection dynamics.	ℹ️ Traditional medicine interaction. No firm evidence of harm. No dose adjustment. Advise patients to inform prescriber of all traditional medicine use.

COMMON ADVERSE EFFECTS

Grouped by system and frequency:

Very Common (≥10% incidence)

System	Adverse Effect	Incidence	Notes
GI	Diarrhoea	~10–20% (oral route > IV)	Most common ADR. Usually mild-to-moderate, self-limiting. Due to disruption of normal gut flora. More frequent with oral ampicillin than IV. Dose-dependent — more common at higher doses and with prolonged courses. Usually resolves within a few days of stopping. If severe, watery, or bloody → rule out C. difficile infection.

Common (1–10% incidence)

System	Adverse Effect	Incidence	Notes
GI	Nausea	~3–10%	More common with oral route. Taking on empty stomach (as required) may worsen nausea in some patients — but should not be taken with food as absorption is reduced. If intolerable, switch to amoxicillin (which can be taken with food).
GI	Vomiting	~1–5%	As above.
GI	Abdominal discomfort / cramps	~1–5%	Usually mild.
Dermatological	Maculopapular rash (non-allergic “ampicillin rash”)	~5–10% in general; up to 70–100% in EBV mononucleosis; ~15–20% with concurrent allopurinol	⚠️ Important clinical distinction: This is a non-IgE-mediated, non-urticarial rash — typically maculopapular, symmetrical, appearing 5–14 days after starting treatment. It is NOT predictive of future anaphylaxis and should NOT be labelled as “penicillin allergy.” Document carefully as “ampicillin-associated non-allergic rash.”
Dermatological	Urticaria (true allergic)	~1–4%	THIS is a true IgE-mediated allergic reaction (immediate, within hours, pruritic wheals). Stop ampicillin. Document as genuine penicillin allergy. Cross-reactivity with all penicillins expected.
Local (injection site)	Pain at IM injection site	~5–10% (IM route)	IM ampicillin is painful. Reduce by deep IM injection into large muscle mass. Adding lidocaine to diluent (if institutionally approved) may help.
Local (injection site)	Phlebitis / thrombophlebitis at IV site	~3–8% (IV route)	More common with concentrated solutions and prolonged peripheral IV use. Rotate IV site every 48–72 hours. Dilute adequately. Infuse over 15–30 minutes rather than rapid push to reduce phlebitis.
GI	Oral candidiasis (thrush)	~1–3%	Due to disruption of normal oral flora. More common with prolonged courses. Treat with topical nystatin or clotrimazole oral trochés.
GI / Genital	Vaginal candidiasis	~1–5% (in women)	Due to disruption of vaginal flora. Treat with topical or oral fluconazole if symptomatic.
Haematological	Eosinophilia (mild, asymptomatic)	~1–3%	Usually an incidental laboratory finding. No treatment needed. Resolves after stopping ampicillin.

Dose-response threshold for common ADRs:

Diarrhoea and GI effects: Clearly dose-dependent. More common at higher oral doses (>2 g/day) and with prolonged courses (>7 days). Lower at standard doses of 1–2 g/day oral.
Maculopapular rash: Not clearly dose-dependent. Occurrence is more related to host factors (EBV infection, allopurinol co-administration, hyperuricaemia) than dose.
Phlebitis: More common with concentrated IV solutions (>30 mg/mL) and prolonged infusion through peripheral IV lines.

SERIOUS ADVERSE EFFECTS

Adverse Effect	Approximate Frequency	Mechanism / Notes	Action Required
⛔ Anaphylaxis	~0.01–0.05% (1 in 2,000 to 1 in 10,000 penicillin courses); fatality rate ~0.001% (1 in 100,000)	IgE-mediated Type I immediate hypersensitivity. Occurs within minutes to 1 hour of dose (especially first IV/IM dose). Symptoms: urticaria, angioedema, bronchospasm, hypotension, cardiovascular collapse.	⛔ Stop ampicillin immediately. Administer Adrenaline (Epinephrine) 0.5 mg IM (1:1000 solution, 0.5 mL) into anterolateral thigh — repeat every 5 minutes if needed. Airway management, IV fluids, antihistamines (chlorpheniramine 10 mg IV), hydrocortisone 200 mg IV. Call for emergency/ICU support. Adrenaline is the FIRST-LINE antidote — available at all levels of healthcare in India including PHCs. ⚠️ Report to PvPI.
⚠️ Acute interstitial nephritis (AIN)	Rare (~0.1–0.5%)	Drug-induced immunological injury to renal tubules. Presents with fever, rash, eosinophilia, rising creatinine, eosinophiluria, sterile pyuria. May occur 1–3 weeks after starting. More common with high-dose, prolonged IV therapy.	Stop ampicillin immediately. Monitor renal function. Most cases resolve after drug withdrawal. Severe cases may require short-course corticosteroids (specialist input). Report to PvPI.
⚠️ Clostridioides difficile-associated diarrhoea (CDAD) / Pseudomembranous colitis	~0.5–2% (higher in elderly, hospitalised, ICU patients; higher with prolonged courses)	Disruption of colonic flora → overgrowth of toxigenic C. difficile. Ranges from mild diarrhoea to fulminant pseudomembranous colitis with toxic megacolon.	Suspect if: profuse watery diarrhoea (≥3 loose stools/day), bloody stools, abdominal pain, fever, leucocytosis — especially if onset during or within 4–8 weeks of ampicillin therapy. Test:C. difficile toxin assay (GDH + toxin A/B or NAAT). Stop ampicillin (if possible). Treat: Oral vancomycin 125 mg q6h × 10 days (first-line for CDAD in India) or oral metronidazole 400 mg q8h × 10 days (less effective but still used in India). ⛔ Do NOT use loperamide/anti-motility agents. Severe/fulminant CDAD — IV metronidazole + oral/rectal vancomycin + surgical consultation. Report to PvPI.
⚠️ Seizures / Neurotoxicity	Rare at therapeutic doses in patients with normal renal function. Risk increases markedly with: renal impairment + high-dose IV therapy (>150 mg/kg/day)	Penicillin-class neurotoxicity: direct CNS irritation. Manifests as myoclonus, tremors, confusion, hallucinations, generalised tonic-clonic seizures. Risk factors: renal failure, high doses, intrathecal administration (contraindicated for ampicillin), elderly, pre-existing seizure disorder.	Stop or reduce ampicillin dose. Treat seizures with IV benzodiazepines (lorazepam 2–4 mg IV, or midazolam). Correct renal dose adjustment. Drug is dialysable — haemodialysis can remove drug if severe toxicity. Report to PvPI.
⚠️ Haemolytic anaemia (Coombs-positive)	Rare (<0.1%)	Drug-induced immune haemolytic anaemia. Positive direct Coombs test. More common with high-dose, prolonged IV therapy (>2 weeks).	Stop ampicillin. Check direct Coombs test, reticulocyte count, haptoglobin, LDH, bilirubin. Most cases resolve after drug withdrawal. Severe haemolysis may require corticosteroids and/or transfusion. Report to PvPI.
⚠️ Leucopenia / Neutropenia / Thrombocytopenia	Rare (<1%). More common with prolonged courses (>2 weeks) at high doses.	Dose-dependent, reversible bone marrow suppression. Usually mild and asymptomatic.	Monitor CBC if treatment exceeds 10–14 days. If neutrophils <1000/μL or platelets <50,000/μL: stop ampicillin or reduce dose. Usually recovers within 3–7 days of discontinuation. Report to PvPI.
⚠️ Serum sickness-like reaction	Rare	Type III hypersensitivity (immune complex-mediated). Presents with fever, urticaria, joint pain (arthralgias), lymphadenopathy, rash — typically 7–21 days after starting.	Stop ampicillin. Symptomatic treatment: antihistamines, NSAIDs for arthralgias, short-course corticosteroids if severe. Document as penicillin allergy (but different mechanism from anaphylaxis — does NOT predict IgE-mediated anaphylaxis on re-exposure, though re-challenge is generally avoided). Report to PvPI.
⚠️ Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)	Extremely rare (<1 in 100,000) — more commonly associated with other drugs (sulfonamides, anticonvulsants) than penicillins.	Severe mucocutaneous reaction.	⛔ Stop ampicillin immediately. Urgent dermatology and burns unit/ICU referral. Supportive care: fluid resuscitation, wound care, pain management. Mortality: SJS ~5%, TEN ~30%. Report to PvPI.
⚠️ Drug reaction with eosinophilia and systemic symptoms (DRESS)	Extremely rare	Severe multisystem drug hypersensitivity — fever, rash, eosinophilia, lymphadenopathy, hepatitis, nephritis, carditis.	⛔ Stop ampicillin immediately. Systemic corticosteroids under specialist supervision. Multiorgan monitoring. Report to PvPI.
⚠️ Jarisch-Herxheimer reaction	Relevant when treating syphilis (rare indication for ampicillin) — not a direct drug toxicity but a host response to rapid spirochetal killing.	Fever, rigors, myalgias, worsening rash — typically within 2–12 hours of first dose when treating syphilis.	Supportive care — antipyretics, fluids. Warn patient in advance if treating syphilis. Do NOT stop the antibiotic. Self-limiting within 24 hours.

Antidote Information:

Toxicity	Antidote	Dose	Availability in India
Anaphylaxis	Adrenaline (Epinephrine) — first-line	0.5 mg IM (1:1000), repeat q5 min as needed. Children: 0.01 mg/kg IM (max 0.3 mg per dose for children <12 years)	✔ Widely available at all levels including PHCs. Must be available wherever injectable antibiotics are administered.
Seizures from neurotoxicity	Lorazepam (first-line anticonvulsant) or Midazolam	Lorazepam 2–4 mg IV (adults); Midazolam 0.1–0.2 mg/kg IV/IM	✔ Available at district hospitals and above.
Severe drug accumulation in renal failure	Haemodialysis — removes 20–50% of drug per session	Standard 4-hour HD session	✔ Available at district hospitals and above with nephrology services.

ℹ️ No specific pharmacological antidote exists for ampicillin overdose beyond supportive care and dialysis for removal.

CDSCO Safety Alerts / Black Box Warnings:
No specific CDSCO black box-equivalent warning exists for ampicillin. The CDSCO product insert includes standard penicillin allergy warnings and advises a test dose before the first injection in patients with uncertain allergy history (note: test dosing is controversial — sensitivity is poor, and it may itself cause anaphylaxis. Current expert practice favours a detailed allergy history and skin testing over test dosing, but test dosing remains widely practised in Indian hospitals).

⚠️ PvPI Reporting: For ALL serious adverse effects listed above: Report to the nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on the CDSCO website (https://www.cdsco.gov.in). Reports can also be submitted via the ADR reporting mobile app or by calling the PvPI helpline.

MONITORING REQUIREMENTS

Baseline (Before Starting)

Parameter	Priority	Details	Resource-Limited Setting Surrogate
Allergy history	MANDATORY	Detailed history of previous penicillin/beta-lactam reactions: type (immediate vs delayed), timing (within 1 hour vs days), morphology (urticaria vs maculopapular), severity (anaphylaxis vs mild rash), and whether rechallenge was ever done. This is the single most important pre-prescribing assessment.	Same — clinical history. No substitute.
Serum creatinine + eGFR/CrCl calculation	MANDATORY (for parenteral therapy and all patients with suspected/known renal impairment) / RECOMMENDED (for short-course oral therapy in young patients with no risk factors)	Required to determine dosing interval. Use Cockcroft-Gault or CKD-EPI. In elderly (≥60 years): always calculate — do NOT rely on serum creatinine alone.	If serum creatinine unavailable: assess urine output (>0.5 mL/kg/hr suggests adequate renal function), history of known kidney disease, presence of oedema, and review of concurrent nephrotoxic drugs. Adjust dose conservatively (extend interval to q8h) if renal function uncertain and patient is elderly or critically ill.
Infection-specific cultures	MANDATORY (for serious infections: meningitis, endocarditis, sepsis, pyelonephritis, intra-abdominal infections) / RECOMMENDED (for UTI, typhoid) / OPTIONAL (for uncomplicated pharyngitis, sinusitis, skin infection)	Blood cultures (×2 sets from separate sites), urine culture, CSF culture, wound culture — as appropriate for the site of infection. Ideally obtained BEFORE starting antibiotics.	If culture facilities unavailable (PHC/CHC setting): start empirical therapy, document clinical diagnosis carefully, and refer for culture if no response at 48–72 hours. For UTI: at minimum, send urine for microscopy (pus cells, bacteria) even without formal culture.
Complete blood count (CBC) with differential	RECOMMENDED	Baseline WBC count, differential (neutrophil count), haemoglobin, platelet count. Helps assess severity of infection and provides baseline for monitoring haematological ADRs in prolonged courses.	If CBC unavailable: clinical assessment of pallor, petechiae, signs of severe infection. Not a substitute for laboratory monitoring in serious infections.
Liver function tests (LFTs)	OPTIONAL but helpful	Baseline AST, ALT, ALP, bilirubin. Useful for comparison if hepatic adverse effects develop. Not mandatory because ampicillin has minimal hepatic metabolism and low hepatotoxicity risk.	Not essential if unavailable. Monitor clinically for jaundice.
Inflammatory markers (CRP, ESR, Procalcitonin)	RECOMMENDED (for serious infections to guide duration and assess response) / OPTIONAL (for mild infections)	CRP is most useful for monitoring response to therapy. Procalcitonin (if available) helps distinguish bacterial from viral infection and guide antibiotic discontinuation.	If CRP/PCT unavailable: monitor clinical response (fever curve, general condition, appetite, sensorium).

For specific indications — additional mandatory baseline:

Indication	Additional Mandatory Baseline
Meningitis	CSF analysis (cell count, protein, glucose, Gram stain, culture). CT brain if signs of raised ICP before LP.
Endocarditis	At least 3 sets of blood cultures. Echocardiography (TTE; TEE if prosthetic valve or poor TTE windows). Baseline hearing assessment (if aminoglycoside planned).
Neonatal sepsis	Blood culture (≥1 mL in paediatric bottle). CBC with differential. CRP (serial at 0 and 24–48 hours). Blood glucose. Serum electrolytes. LP (CSF) — recommended for all suspected LONS and when meningitis is clinically possible.
Enterococcal UTI	Urine culture and sensitivity (MANDATORY). Renal ultrasound if complicated/febrile UTI.

After Initiation / Dose Change

Parameter	Timing	Details
Clinical response assessment	48–72 hours after starting therapy	Fever curve, haemodynamic stability, improvement in organ-specific symptoms (sensorium in meningitis, respiratory function in pneumonia, abdominal signs in peritonitis). If no improvement at 72 hours → reassess: check culture results, consider resistant organism, alternative diagnosis, or complication.
Repeat cultures	48–72 hours (for bloodstream infections, endocarditis, meningitis)	Repeat blood cultures to document clearance. Repeat CSF in meningitis (especially Gram-negative) at 48–72 hours to document sterilisation. Endocarditis: daily blood cultures until first negative culture, then every 48 hours until 3 consecutive negative sets.
Serum creatinine / eGFR	Day 3–5 (for patients on IV therapy, especially if combined with gentamicin or other nephrotoxic drugs)	Recheck to ensure no deterioration. If eGFR has declined, extend ampicillin dosing interval and reassess gentamicin dosing/need.
CBC	Day 5–7 (if course expected to exceed 7 days)	Monitor for leucopenia, neutropenia, thrombocytopenia, eosinophilia.
CRP	Day 3–5 (for serious infections)	Declining CRP supports adequate treatment response. Persistently elevated or rising CRP suggests treatment failure or complication.

Long-Term / Maintenance Monitoring

Parameter	Frequency	Details
CBC with differential	Weekly if therapy exceeds 10–14 days (endocarditis, Listeria meningitis, bone and joint infections)	Prolonged high-dose ampicillin can cause reversible leucopenia, neutropenia, thrombocytopenia, or haemolytic anaemia. Check weekly.
Serum creatinine / eGFR	Weekly during prolonged IV courses	Monitor for acute interstitial nephritis (AIN). Especially important if co-administered with aminoglycosides.
LFTs	Every 1–2 weeks during prolonged IV courses (>2 weeks)	Monitor for drug-induced hepatitis (rare with ampicillin but possible).
Direct Coombs test	If haemolysis suspected (falling Hb with reticulocytosis, elevated LDH, low haptoglobin)	Not routine — only if clinical or laboratory signs of haemolysis develop.
Stool monitoring	Ongoing — clinical assessment	If diarrhoea develops (≥3 loose stools/day), especially if bloody or with fever → test for C. difficile toxin.
IV site assessment	Every shift (q8–12 hours) for nursing staff	Check for phlebitis, infiltration, extravasation. Rotate peripheral IV site every 48–72 hours. For prolonged IV therapy (endocarditis >2 weeks): consider PICC line insertion.

For endocarditis specifically (prolonged therapy):

Parameter	Frequency	Details
Gentamicin trough levels (if using Regimen A)	2–3 times per week initially, then weekly once stable	Target trough <1 mcg/mL. ⚠️ Supratherapeutic troughs → nephrotoxicity and ototoxicity.
Audiometry	Weekly (if using gentamicin)	Detect early high-frequency hearing loss.
Repeat echocardiography	As clinically indicated (at 1–2 weeks, at end of treatment, and if clinical deterioration)	Monitor vegetation size, valvular function, abscess formation.

Therapeutic Drug Monitoring (TDM)

ℹ️ Routine TDM for ampicillin is NOT standard practice. Ampicillin has a wide therapeutic index, and dose adjustments are made based on renal function and clinical response rather than serum levels.

TDM may be considered in the following situations (when available):

ICU patients with augmented renal clearance (ARC) — to confirm adequate levels are being achieved
Patients with severe renal impairment on haemodialysis — to avoid accumulation
CNS infections (meningitis) in patients with unusual PK (obese, post-neurosurgical, CSF shunt) — to confirm adequate CSF penetration
Prolonged courses (endocarditis) in patients with fluctuating renal function

Target levels (if TDM available):

No universally established target trough for ampicillin. The key PK/PD target is fT > MIC ≥ 40–50% of the dosing interval. For most susceptible organisms (MIC ≤ 2 mcg/mL), standard dosing achieves this target with normal renal function.
A trough level > 2–4 times the MIC of the organism is a reasonable target for serious infections.

When to stop monitoring: Monitoring (CBC, creatinine, LFTs) can be relaxed when:

The antibiotic course is completed
For courses <7 days in patients with normal renal function: no repeat monitoring necessary unless clinical concern arises

Resource-limited setting surrogates:

Monitoring Parameter	Clinical Surrogate When Test Unavailable
Serum creatinine / eGFR	Urine output monitoring (>0.5 mL/kg/hr). History of oliguria/anuria. Presence of oedema.
CBC	Clinical signs of anaemia (pallor, tachycardia), bleeding (petechiae, gum bleeding), infection worsening despite treatment (possible neutropenia).
LFTs	Clinical jaundice, dark urine, clay-coloured stools, right upper quadrant tenderness.
CRP	Fever curve as primary surrogate. Subjective improvement (appetite, activity level, pain).
Blood culture	Gram stain (if microscopy available). Clinical response to empirical therapy.

PATIENT COUNSELLING

(Written in simple language for the prescribing doctor to convey to the patient during consultation)

What this medicine is for:
“This medicine is an antibiotic — it kills the bacteria (germs) that are causing your infection. It works against many common types of bacteria. It will NOT work against viruses (such as common cold or flu).”

How to take it:

For oral capsules/suspension:

“Take this medicine on an empty stomach — either 1 hour before eating or 2 hours after eating. Food reduces how well the medicine works.”
“Take each dose with a full glass of water.”
“Swallow the capsule whole — do not break or chew it.”
“If you are taking the liquid (syrup), shake the bottle well before each dose. Use the measuring cup or syringe given with the bottle — do NOT use a household spoon (it will give the wrong amount).”
“Take the medicine at evenly spaced times — for example, if you take it 4 times a day, take it every 6 hours (e.g., 6 AM, 12 noon, 6 PM, 12 midnight).”
“Complete the full course as prescribed by your doctor, even if you feel better before the course is finished. Stopping early can allow the infection to come back, and the bacteria may become resistant to this medicine.”

What to do if you miss a dose:

“If you remember within 3 hours of the missed time, take the dose immediately. Then continue with your regular schedule.”
“If more than 3 hours have passed, skip the missed dose and take the next one at the regular time.”
“Never take two doses at the same time to make up for a missed dose.”

Common side effects to expect:

“You may get loose stools or diarrhoea — this is common and usually mild. Drink plenty of fluids (water, ORS, coconut water, buttermilk/chaas). If the diarrhoea is very severe, watery, bloody, or lasts more than 2 days, see your doctor.”
“You may feel mild nausea or stomach discomfort — this usually gets better after a few days.”
“Some people get a rash (red spots on the skin) after about 1–2 weeks of taking this medicine. This is usually not a dangerous allergy, but you should tell your doctor about it.”

Warning signs — come to hospital immediately if you develop any of these:

⚠️ “Difficulty breathing, swelling of the face/lips/tongue/throat, or feeling like your throat is closing — this could be a serious allergic reaction. Go to the nearest hospital immediately.”
⚠️ “Severe skin rash with blisters, peeling skin, or sores in the mouth — stop the medicine and go to hospital.”
⚠️ “Severe diarrhoea (bloody or watery, many times a day) with fever and stomach pain — see your doctor urgently.”
⚠️ “Yellow colour of the eyes or skin (jaundice) — see your doctor.”
⚠️ “Unusual bruising or bleeding — see your doctor.”
⚠️ “Fits (seizures/convulsions) — go to hospital.”

Things to avoid:

“Do not take this medicine with food — it must be taken on an empty stomach.”
“There is no specific restriction on alcohol, but alcohol may worsen nausea and stomach discomfort. It is best to avoid alcohol while you are unwell with an infection.”
“Do not take any other medicines (including medicines bought from the chemist without prescription, and any Ayurvedic or herbal medicines) without telling your doctor — some medicines may interact.”

Storage:

Capsules: “Store at room temperature in a cool, dry place. Keep away from moisture and direct sunlight. Keep out of reach of children.”
Reconstituted oral suspension (liquid): “After the chemist adds water to the powder, store the bottle in the fridge. If you do not have a fridge, keep it in the coolest part of your house — away from the kitchen, stove, and windows. Use within 7 days (check the label). After 7–14 days, throw away any leftover liquid.”
ℹ️ Indian hot climate note: “In summer, the medicine may spoil faster if left at room temperature. Try to keep it cool. If the liquid looks or smells different, do not use it.”

Duration:

“This medicine is for a specific course to treat your infection — it is NOT a long-term medicine.”
“Your doctor will tell you how many days to take it. Please complete the full course.”
“Do NOT stop early even if you feel better — the infection may come back and be harder to treat.”

Follow-up:

“Come back to your doctor if you are not feeling better after 3 days of taking this medicine.”
“Come back for any blood tests or check-ups your doctor has asked for.”
“If you are taking this medicine for a long time (more than 2 weeks), your doctor may ask for blood tests to check your kidneys and blood counts.”

Common Patient Questions:

“Can I take this with my other medicines?”
“Tell your doctor about ALL medicines you are taking — including medicines for gout (allopurinol), blood thinning medicines (warfarin), cancer medicines (methotrexate), or any other tablets. Some medicines need dose changes or extra monitoring when taken together.”

“Can I take this during fasting (Ramadan / Navratri / Ekadashi)?”
“This medicine needs to be taken 4 times a day, evenly spaced (every 6 hours). During fasting, it may be difficult to take all 4 doses, especially since it must be taken on an empty stomach. Talk to your doctor — they may switch you to a different antibiotic that is taken fewer times a day (such as amoxicillin 3 times a day or a different antibiotic taken once or twice daily). Do NOT skip doses during fasting — incomplete antibiotic courses can cause the infection to return.”

“Will this affect my ability to drive or work?”
“This medicine usually does NOT cause drowsiness or affect your ability to drive or work. If you feel dizzy or unwell (due to the infection itself, not the medicine), avoid driving until you feel better.”

“Is this medicine habit-forming?”
“No. Antibiotics are not habit-forming medicines. You will take them for a specific number of days and then stop.”

“Can I stop once I feel better?”
“No — please complete the full course even if you feel better. Stopping early can allow the infection to come back. The bacteria may also become resistant, meaning the same medicine may not work next time.”

Caregiver / Family Counselling:

(For paediatric patients, elderly with cognitive impairment, or ICU patients)

“Counsel the caregiver/family member on:”

✔ How to give the correct dose — use the measuring cup or syringe provided, NOT a household spoon.
✔ Timing — every 6 hours, on an empty stomach. Set alarms on a phone if needed.
✔ Shaking the suspension bottle well before each dose.
✔ Storing the liquid in the fridge (or coolest spot if no fridge).
✔ Warning signs to watch for in the child or elderly patient: difficulty breathing, swelling of face, severe rash, severe diarrhoea, fits (seizures), reduced urine output, drowsiness/confusion, refusing feeds. Bring to hospital immediately if any of these occur.
✔ Completing the full course — even if the child seems well.
✔ Do NOT share this antibiotic with another family member or save leftover doses for future illness.

India-specific adherence support:

💡 Cost-driven non-adherence:
“If cost is a concern, ask your doctor about generic ampicillin from Jan Aushadhi (PMBJP) stores — it is the same medicine at a much lower price. Jan Aushadhi stores are available in most district towns.”

💡 Stigma: Not typically applicable for ampicillin (no social stigma associated with antibiotic use).

💡 Polypharmacy burden:
“If you are taking many medicines, ask your doctor to review which ones are essential. Write down all your medicines and doses on a piece of paper and carry it with you to every doctor visit.”

💡 Temperature-sensitive drug in hot climate:
“The liquid form (suspension) must be kept cool. In summer, wrap the bottle in a damp cloth and keep in the coolest part of your house if you do not have a fridge. Do not leave it in a car or near a window.”

💡 Rural access — what to do if you can’t get a refill on time:
“If you cannot get more medicine before your current supply runs out, do NOT reduce the dose to ‘stretch’ the course. Instead, contact your doctor or the nearest Primary Health Centre for help. Stopping early or reducing the dose can cause the infection to return.”

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP Brands:

Brand Name	Formulation	Manufacturer / Supplier	Availability
Ampicillin Capsules (Jan Aushadhi)	Capsules 250 mg, 500 mg	PMBJP approved suppliers (Bureau of Pharma PSUs of India — BPPI contracted)	Available at Jan Aushadhi Kendras across India. Availability may vary by centre.
Ampicillin Powder for Injection (Jan Aushadhi)	500 mg vial	PMBJP contracted supplier	Available at Jan Aushadhi Kendras.
Ampicillin Oral Suspension (Jan Aushadhi)	125 mg/5 mL dry syrup	PMBJP contracted supplier	Limited availability — not stocked at all centres.

ℹ️ Jan Aushadhi availability for ampicillin formulations exists but may not include all strengths at all centres. Verify at the nearest Jan Aushadhi Kendra or via the PMBJP website/app (janaushadhi.gov.in).

Major Private Brands:

Brand Name	Manufacturer	Formulations Available	Availability
Ampicillin (generic)	Multiple manufacturers	Capsules 250 mg, 500 mg; Injection 250 mg, 500 mg, 1 g; Oral suspension 125 mg/5 mL, 250 mg/5 mL	Widely available
Ampicillin (Cadila / Zydus)	Zydus Cadila	Capsules 250 mg, 500 mg; Injection 500 mg, 1 g	Widely available
Biocillin	Biochem Pharmaceutical Industries	Capsules 250 mg, 500 mg	Widely available
Ampilin	Various (multiple small manufacturers)	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL	Widely available
Roscillin	Tablets India Ltd	Capsules 500 mg	Major metros and Tier-2 cities
Campicillin	AGIO Pharmaceuticals	Capsules 250 mg, 500 mg; Injection 500 mg	Widely available

Ampicillin + Sulbactam FDC Brands (commonly prescribed):

Brand Name	Manufacturer	Formulations	Availability
Magnex	BDR Pharmaceuticals	Injection: 1.5 g (1 g + 0.5 g), 3 g (2 g + 1 g)	Widely available
Sultamicillin (oral FDC) — Unasyn (oral), others	Pfizer, multiple generics	Tablets 375 mg	Major metros and Tier-2 cities
Ampisyn-SB	Intas Pharmaceuticals	Injection: 1.5 g, 3 g	Widely available
Ampilox-SB	Various	Injection: 1.5 g, 3 g	Widely available

Ampicillin + Cloxacillin FDC Brands:

Brand Name	Manufacturer	Formulations	Availability
Ampicilox / Ampilox	Various manufacturers	Capsules: 250 mg + 250 mg; Injection: 250 mg + 250 mg, 500 mg + 500 mg	Widely available
Megapen	Aristo Pharmaceuticals	Capsules: 250 mg + 250 mg; Injection: 500 mg + 500 mg	Widely available

ℹ️ CDSCO regulatory note: As of the latest CDSCO banned drug list (verified against Gazette of India notifications), no single-ingredient ampicillin formulation has been banned or withdrawn. Certain irrational FDCs involving ampicillin with other antibiotics (beyond sulbactam and cloxacillin) may have been restricted — always verify against the current CDSCO banned drug list. No Not of Standard Quality (NSQ) alerts for specific brands listed above are current as of the date of this monograph — however, the CDSCO website should be checked for the latest NSQ alerts.

PRICE RANGE (INR)

Prices as of June 2025. Verify current prices on NPPA/1mg/PharmEasy/Jan Aushadhi price lists as prices may change.

Single-Ingredient Ampicillin:

Formulation	Strength	Private Retail Price (approx. per unit)	Jan Aushadhi / PMBJP Price (approx. per unit)	NPPA Controlled?
Capsule	250 mg	₹2–4 per capsule	₹0.80–1.50 per capsule	✔ Yes — NLEM-listed. Ceiling price fixed by NPPA under DPCO.
Capsule	500 mg	₹4–8 per capsule	₹1.50–3.00 per capsule	✔ Yes — NLEM-listed.
Dry Syrup (Oral Suspension)	125 mg/5 mL (60 mL bottle)	₹25–50 per bottle	₹15–25 per bottle	✔ Yes — NLEM-listed.
Dry Syrup (Oral Suspension)	250 mg/5 mL (60 mL bottle)	₹35–70 per bottle	₹20–35 per bottle	✔ Yes — NLEM-listed.
Injection (Powder for Injection)	250 mg vial	₹8–20 per vial	₹5–10 per vial	✔ Yes — NLEM-listed.
Injection (Powder for Injection)	500 mg vial	₹15–35 per vial	₹8–18 per vial	✔ Yes — NLEM-listed.
Injection (Powder for Injection)	1 g vial	₹25–60 per vial	₹15–30 per vial	✔ Yes — NLEM-listed.

Estimated Per-Course / Per-Month Cost:

Clinical Scenario	Dose	Duration	Estimated Private Retail Cost	Estimated Jan Aushadhi Cost
Oral: Mild infection (adult)	500 mg q6h	7 days (28 capsules)	₹110–225 per course	₹42–85 per course
IV: Moderate infection (adult)	1 g q6h	7 days (28 vials of 1 g)	₹700–1,680 per course	₹420–840 per course
IV: Meningitis (adult)	2 g q4h (= 12 g/day)	21 days (126 vials of 1 g, 2 vials per dose)	₹3,150–7,560 per course	₹1,890–3,780 per course
IV: Endocarditis (adult)	2 g q4h	42 days (6 weeks) (252 vials of 1 g)	₹6,300–15,120 per course	₹3,780–7,560 per course
Oral: Paediatric mild infection	Suspension 125 mg/5 mL	7 days (~2 bottles)	₹50–100 per course	₹30–50 per course
IV: Neonatal sepsis	50 mg/kg/dose q8h (3 kg neonate = 150 mg q8h)	7 days (~21 doses, using 250 mg vials)	₹170–420 per course	₹105–210 per course

ℹ️ NPPA price control note: Ampicillin (all formulations) is included in the National List of Essential Medicines (NLEM) India, 2022 edition. Its price is regulated by the National Pharmaceutical Pricing Authority (NPPA) under the Drug Price Control Order (DPCO). Ceiling prices are notified periodically. Manufacturers cannot charge above the NPPA-notified ceiling price + local taxes.

ℹ️ Government supply pricing: Ampicillin is available through government hospital pharmacies and Jan Aushadhi stores at significantly lower prices than private retail. Patients attending government hospitals typically receive ampicillin free of cost.

💡 Cost comparison with alternatives:

Oral ampicillin is comparable in cost to oral amoxicillin (also NLEM-listed). Amoxicillin is preferred for most oral indications due to better bioavailability — the cost difference is negligible.
Ampicillin-sulbactam injection (1.5 g vial) costs approximately ₹40–120 per vial (private), ₹20–50 (Jan Aushadhi) — modestly more expensive than plain ampicillin injection but provides beta-lactamase coverage.

CLINICAL PEARLS

💡 1. Oral amoxicillin is almost always preferred over oral ampicillin — know when ampicillin is specifically needed.[Evidence-based]
Amoxicillin has 70–90% oral bioavailability vs ampicillin’s 40–50%, is less affected by food, and can be dosed q8h instead of q6h — improving adherence and achieving better serum levels. The ONLY situations where ampicillin (not amoxicillin) is specifically needed are: (a) IV/IM use (ampicillin sodium is the standard parenteral aminopenicillin — IV amoxicillin is not widely available in India); (b) rare situations where the specific pharmacokinetic profile of ampicillin is desired (essentially none in routine practice). For oral use, always prefer amoxicillin unless there is a specific reason to use ampicillin.

💡 2. Ampicillin rash ≠ penicillin allergy — document correctly or the patient loses access to penicillins for life.[Evidence-based]
The maculopapular, non-pruritic rash occurring 5–14 days after starting ampicillin is a non-IgE-mediated reaction (especially common with concurrent EBV mononucleosis or allopurinol). It does NOT predict future anaphylaxis and should NOT be documented as “penicillin allergy” in the medical records. Mislabelling this as allergy leads to lifelong avoidance of all penicillins (including amoxicillin, piperacillin-tazobactam) — forcing use of broader-spectrum, more expensive, and often less effective alternatives. Document as: “Ampicillin-associated non-allergic maculopapular rash — NOT IgE-mediated penicillin allergy.”

💡 3. Never mix ampicillin and gentamicin in the same IV line — but in the body, they are synergistic.[Evidence-based]
This is a common error in Indian hospitals: nursing staff mixing ampicillin and gentamicin in the same IV bag for convenience (since they are co-prescribed in neonatal sepsis and enterococcal infections). Ampicillin chemically inactivates aminoglycosides within minutes if mixed in the same solution → the gentamicin becomes ineffective. Always give separately with a saline flush between them. In vivo, the combination provides excellent synergistic bactericidal activity against Enterococci, Listeria, and GBS.

💡 4. Myth vs Fact: “A test dose of penicillin/ampicillin injection prevents anaphylaxis.”
Myth: Many Indian hospitals administer a “test dose” (intradermal or tiny IV dose) before the full first dose of ampicillin/penicillin injection, believing it will identify allergic patients safely.
Fact: Test dosing has poor sensitivity and poor predictive value. A negative test dose does NOT rule out anaphylaxis — false negatives are common. Conversely, the test dose itself can trigger fatal anaphylaxis in a truly allergic patient. Current best practice (endorsed by most allergology and infectious disease experts) is: (a) Take a detailed allergy history; (b) If the history is suggestive of IgE-mediated allergy, perform formal penicillin skin testing (where available) or use an alternative antibiotic; © If the history is NOT suggestive, give the full dose with standard anaphylaxis monitoring (have adrenaline available). Despite this, test dosing remains widespread in Indian hospitals — prescribers should be aware of its limitations. [Evidence-based — supported by international allergology guidelines and expert consensus]

💡 5. In Indian ICUs, consider augmented renal clearance (ARC) — your ampicillin may be underdosed.[Practice-based]
Young, non-elderly ICU patients with sepsis, trauma, or burns commonly develop ARC (CrCl >130 mL/min). This leads to subtherapeutic ampicillin levels with standard q6h dosing. Consider q4h dosing, higher individual doses (2 g q4h), or even continuous/prolonged infusion in critically ill patients not responding to standard regimens. Measure an 8-hour CrCl from timed urine collection if ARC is suspected. This is an under-recognised cause of apparent treatment failure in Indian ICU practice.

💡 6. For Enterococcal infections, ampicillin susceptibility is your friend — don’t reach for vancomycin reflexively.[Practice-based]
In Indian hospitals, there is an increasing tendency to use vancomycin empirically for Gram-positive infections. However, for E. faecalis (the most common Enterococcal species in Indian clinical isolates), ~80–90% of isolates remain ampicillin-susceptible. Ampicillin is more effective, less toxic, and far cheaper than vancomycin for susceptible Enterococcal infections. Reserve vancomycin for confirmed VRE, E. faecium (usually ampicillin-resistant), or when true beta-lactam allergy exists. Always check ampicillin susceptibility on the culture report before escalating to vancomycin.

VERSION

RxIndia v0.1 — 15 Mar 2026

REFERENCES

Listed below are the sources actually used or referenced in generating this monograph:

CDSCO Product Insert — Ampicillin Capsules and Ampicillin Sodium Injection (multiple manufacturers; representative insert from Cadila Healthcare Ltd / Zydus Cadila). CDSCO-approved labelling for indications, dosing, contraindications, and adverse effects.
Indian Pharmacopoeia 2022 — Indian Pharmacopoeia Commission. Monograph: Ampicillin (anhydrous), Ampicillin trihydrate, Ampicillin sodium. Drug standards, identification, assay.
National List of Essential Medicines (NLEM) India, 2022 — Ministry of Health and Family Welfare, Government of India. Ampicillin listed under Section 6.2 (Antibacterials — Beta-lactam medicines).
National Formulary of India, 6th Edition (2021) — Indian Pharmacopoeia Commission. Ampicillin monograph: indications, dosing, adverse effects, pharmacokinetics, drug interactions.
ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes, 2019 — Indian Council of Medical Research. Guidance on empirical antibiotic selection for common infections including UTI, pneumonia, meningitis, enteric fever, and neonatal sepsis. Resistance data and recommendations for India-specific antibiotic stewardship.
API Textbook of Medicine, 11th Edition — Association of Physicians of India. Chapters on: Bacterial Meningitis, Infective Endocarditis, Community-Acquired Pneumonia, Urinary Tract Infections, Enteric Fever, Spontaneous Bacterial Peritonitis, Peritonitis, Obstetric Infections.
IAP (Indian Academy of Pediatrics) Guidelines:
- IAP Guidelines on Management of Community-Acquired Pneumonia in Children (revised 2021).
- IAP Guidelines on Urinary Tract Infections in Children.
- IAP Neonatology Chapter — Guidelines on Neonatal Sepsis.
NNF (National Neonatology Forum of India) Clinical Practice Guidelines — Neonatal Sepsis: Diagnosis and Management (latest edition). Empirical antibiotic regimens for EONS and LONS, neonatal meningitis dosing.
WHO Pocket Book of Hospital Care for Children, 2nd Edition (2013) — World Health Organization. Neonatal and paediatric dosing for ampicillin + gentamicin. Integrated Management of Childhood Illness (IMNCI) guidelines.
FOGSI (Federation of Obstetric and Gynaecological Societies of India) Guidelines — Intrapartum GBS prophylaxis, chorioamnionitis management, PPROM latency antibiotics, postpartum endometritis.
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023) — Brunton LL, Knollmann BC (editors). Chapter: Penicillins, Cephalosporins, and Other β-Lactam Antibiotics. Pharmacology, mechanism of action, PK/PD principles of beta-lactams, time-dependent killing, spectrum of activity.
Harrison’s Principles of Internal Medicine, 21st Edition (2022) — Jameson JL, Fauci AS, Kasper DL, et al. (editors). Chapters: Treatment of Bacterial Infections, Meningitis, Infective Endocarditis, Pneumonia, UTI, Enteric Fever, Intra-abdominal Infections.
AIIMS Treatment Guidelines / Protocols — All India Institute of Medical Sciences, New Delhi. Referenced for: Empirical meningitis management, Infective Endocarditis treatment protocols, Neonatal sepsis management, Surgical infectious disease protocols (intra-abdominal infections).
NPPA (National Pharmaceutical Pricing Authority) — Drug Price Control Order (DPCO) — Ceiling price notifications for ampicillin formulations. Available at nppaindia.nic.in.
PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Product catalogue and pricing. Available at janaushadhi.gov.in.
CDSCO Banned Drugs List — Gazette of India notifications on banned/restricted fixed-dose combinations. Reviewed to confirm no ampicillin single-ingredient or approved FDC ban status.
PvPI (Pharmacovigilance Programme of India) — ADR reporting guidelines and mechanism. Central Drugs Standard Control Organisation. Available at cdsco.gov.in.
Mercer BM, et al. (1997) — “Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes.” JAMA; 278(12):989–995. (Referenced for PPROM latency antibiotic regimen — off-label indication.)
ORACLE Collaborative Group (2001) — Kenyon SL, et al. “Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial.” Lancet; 357(9261):979–988. (Referenced for PPROM latency antibiotic evidence and the warning against amoxicillin-clavulanate in PPROM.)
Fernandez-Hidalgo N, et al. (2013) — “Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis.” Clin Infect Dis; 56(9):1261–1268. (Referenced for the ampicillin + ceftriaxone regimen for Enterococcal IE — off-label combination evidence.)
Indian Paediatric Nephrology Group (IPNG) Guidelines — UTI management in children. Referenced for paediatric UTI evaluation and treatment.
ISPD (International Society for Peritoneal Dialysis) Guidelines — PD-related peritonitis prevention and treatment (2022 update). Referenced for intraperitoneal ampicillin dosing in PD peritonitis.

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...